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A B S T R A C T   
Background: Fucoxanthin is a pigment present in diverse marine organisms such as micro and macro-algae. The 
most relevant source of fucoxanthin has been described to be the group of the brown macroalgae, also known as 
Phaeophyceae. The presence of the fucoxanthin, a xanthophyll, found as an accessory pigment in the chloroplasts 
of the brown algae is responsible for providing them their characteristic color. The market size of this carotenoid, 
expected to reach US$ 120 million by 2022, reflects its industrial importance, especially remarkable as a food or 
cosmetic ingredient. 
Scope and approach: Therefore, it is critical to recognize the main sources of fucoxanthin as well as the most 
efficient extraction and purification methods that allow obtaining the best production ratio for such a valuable 
molecule. Throughout this review very different preventive properties of the fucoxanthin have been included, 
such as antioxidant, anticancer, antiangiogenic, anti-inflammatory, cytoprotective, antiobesity, neuroprotective 
and its skin protective effects. The stability, bioavailability and toxicity of the fucoxanthin have also been 
reviewed through diverse biological, in vitro and in vivo assays. 
Key findings and conclusions: Thus, the main aim of this work is to provide a wide and global vision of the 
fucoxanthin in terms of productive species, efficient recovery techniques and multiple industrial applications.   
1. Algae as a source of fucoxanthin 
Approximated 70% of the surface of the Earth is covered by marine 
water. Over the last decades, marine organisms have been revealed as a 
promising source of functional compounds, beneficial for our organism 
and human health, such as vitamins, and essential minerals, dietary fi-
bers, omega-3 polyunsaturated fatty acids (PUFAs), besides a large 
number of peptides, enzymes, and antioxidant substances. Thus, the 
biodiversity contained in the oceans is contemplated as a provider of 
unknown molecules with potential bioactivities to discover (Heo et al., 
2008). Marine resources, such as algae, microalgae or seaweeds have 
been traditionally used as nutrients or remedies. In fact, scientific evi-
dence supports the use of different marine organisms, from distant 
coastal areas since 14000 AD with medicinal and nutritional purposes 
(Dillehay et al., 2008). Algae have been part of the Eastern diet since 
immemorial times, due to its high nutritional content (Dawczynski et al., 
2007), which have prompted their utilization as a food ingredient all 
over the world (Kummar et al., 2008; Soo-Jin You-Jin et al., 2008). In 
the eastern countries, the most used algae for this purpose are Undaria, 
Porphyra and Laminaria genera, colloquially known as wakame, nori, 
and kombu, respectively. Their inclusion in the diet has been general-
ized and its consumption has triggered the controlled production of 
species of interest which are also considered prolific and sustainable 
organisms. Thus, algae aquaculture is undergoing an important evolu-
tion that allows manufacturing huge amounts of algae, exceeding 
exponentially those obtained by manual collection. In addition to this 
ancestral use in food, algae contain other compounds, such as hydro-
colloids, which have been widely applied in pharmaceutical and/or 
cosmetic industries (Kummar et al., 2008). Hence, algae are focusing the 
attention of different research and industry areas in order to magnify 
their use as a possible source of compounds with bioactive potential, 
such as fatty acids, carotenoids, polysaccharides, phytosterols, pheno-
lics, etc., since these are molecules associated with many beneficial 
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PAR photosynthetically active solar radiation 
DW dry weight 
WAT white adipose tissue 
BAT brown adipose tissue 
UV ultraviolet 
EC50 half maximal effective concentration 
IC50 half maximal inhibitory concentration 
LD50 median lethal dose 
ROS reactive oxygen species 
CNS central nervous system 
UVB ultraviolet B-rays 
JAK-STAT Janus kinases signal transducer and activator of 
transcription proteins pathway 
PI3K/Akt intracellular signal transduction pathway 
MAPKs mitogen-activated protein kinase pathway 
I/R ischemia/reperfusion injury 
ARE antioxidant response elements 
TBI traumatic brain injury 
SHRSP stroke-prone spontaneously hypertensive rats 
NF-kB nuclear factor kappa-light-chain-enhancer of activated B 
cells pathway 
KEGG Kyoto Encyclopedia of Genes and Genomes 
mTOR mammalian target of rapamycin 
MAPK mitogen-activated protein kinase 
Wnt wingless and int-1 signaling pathways 
Hippo Salvador-Warts-Hippo pathway 
Notch Notch signaling pathway 
FoxO Forkhead box protein O1 
PUFAs omega-3 polyunsaturated fatty acids 
NAD(P)+ nicotinamide adenine dinucleotide phosphate 
EtOH ethanol 
DE diethyl ether 
H2O2 hydrogen peroxide 
Nrf2 nuclear factor erythroid 2-related factor 2 
NQO1 quinine oxidoreductase 
DEN diethylnitrosamine 
HO-1 heme oxygenase-1 
AMPK activated protein kinase 
LDL low-density lipoprotein 
Bcl-xL anti-apoptotic protein 
ADP adenosine diphosphate 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
NO nitric oxide 
iNOS inducible nitric oxide synthase 
COX-2 cyclooxygenase 2 
TNF-α tumor necrosis factor-α 
RNA ribonucleic acid 
DNA deoxyribonucleic acid 
PAI-1 plasminogen activator inhibitor-1 
UPC1 mitochondrial uncoupling protein 1 
DHA docosahexaenoic acid 
Adrb3 β3-adrenergic receptor 
GLUT4 glucose transporter 4 
MCP-1 monocyte chemoattractant protein-1 
HRAR recombinant aldose reductase 
RLAR rat lens aldose reductase 
PTP1B protein tyrosine phosphatase 1B 
AGE advanced glycation end-product 
NAC N- acetylcysteine 
TAG long-chain triacylglycerols 
C chitosan 
G glycolipid 
ST sodium tripolyphosphate 
Techniques 
P-TLC preparative thin layer chromatography 
NMR nuclear Magnetic Resonance 
HPLC high-performance liquid chromatography 
LC liquid chromatography 
DAD photodiode-array detector 
MS mass spectrometry 
DPPH 2,2-diphenyl-1-picryl-hydrazyl-hydrate free radical assay 
FRAP ferric reducing antioxidant power assay 
ABTS 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
assay 
Cellular lines 
CaCo-2 human colon epithelial cancer cell line 
Hep G2 human liver carcinoma cell line 
Vero kidney fibroblast cells from monkey 
BNL CL.2 murine hepatic cells from mouse 
3 T3-L1 adipocytes from mouse 
SH-SY5Y human neuroblastoma cell line 
L02 human hepatic cell line 
B16-F10 melanoma mouse cell line 
BNL CL.2 embryonic liver mouse cell line 
Neuro2a neuroblastoma murine cell line 
HL-60 human leukemia cell line 
DLD-1 colorectal adenocarcinoma cell line 
HT-29 colorectal adenocarcinoma cell line 
HCT116 human colorectal carcinoma cell line 
PC-3 human prostate cancer cell lines 
DU145 human prostate cancer cell line 
LNCaP human prostate adenocarcinoma cell line 
MCF-7 breast cancer cell line 
MDA-MB-231 epithelial, human breast cancer cell line 
HUC-Fm human male umbilical cord fibroblasts 
EJ-1 urinary bladder cancer cell line 
GOTO human neuroblastoma 
SK-Hep-1 immortal human cell line 
H1299 lung cancer cell line 
WiDr human colon carcinoma 
U87 primary glioblastoma cell line 
U251 human glioblastoma astrocytoma cell line 
SGC-7901 human gastric cancer cell line 
BGC-823 human gastric carcinoma cell line 
NSCLC-N6 non-small-cell lung carcinoma cell line 
K562 myelogenous leukemia cell line 
TK6 human lymphoblastoid cell line 
HeLa human cervical adenocarcinoma cell line 
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health effects, such as anticoagulant, antitumor properties (Saet et al., 
2008) or antioxidants (Kummar et al., 2008). Therefore, the develop-
ment of new functional ingredients for food, cosmetic and pharmaceu-
tical formulations (Perez-Gregorio & Simal-Gandara, 2017) from 
compounds present in algae are gaining importance. The studies carried 
out with brown algae are the ones that reported the greatest amount of 
bioactive components, surpassing red and green ones (Prabhasankar 
et al., 2009). An example of such interesting compounds are phlor-
otannins, phylopheophylin, and fucoxanthin, among other metabolites 
(Maeda et al., 2006). 
Fucoxanthin is a compound belonging to the group of carotenoids, 
considered a secondary metabolite and one of the most abundant and 
characteristic pigments of brown algae. Some examples of edible algae 
that contain fucoxanthin belong to the genera Undaria, Sargassum, 
Laminaria, Eisenia, Alaria, Cystoseira, or Hijikia (Maoka et al., 2007; 
Willstatter & Page, 1914). Nevertheless, it has been also found in large 
quantities in other matrices such as the diatom Phaeodactylum tricornu-
tum (Li et al., 2018). 
Fucoxanthin is a pigment present in chloroplasts of eukaryotic algae 
Chromalveolata (phylum Heterokontophyta, Ochrophyta class) 
involved in the photosynthesis process which is considered to be more 
productive than that occurring in the most efficient land plants (Gao & 
McKinley, 1994). Besides, it is a very abundant molecule, it accounts for 
approximately 10% of the total carotenoids in nature (Maeda et al., 
2006). Currently, the market size of this pigment maintains an average 
annual growth rate of 2.47% which in American dollars represented a 
rise from 92 million $ in 2014 to 99 million $ in 2017. Scientific analysts 
have estimated a future expansion of the fucoxanthin market size that 
may reach 120 million $ by 2022 (Market Reports World, 2017). 
The biological and therapeutic activities related to this carotenoid 
have been repeatedly underlined throughout scientific works that have 
reported its antioxidant, anticancer, antihypertensive, anti- 
inflammatory, anti-diabetic, anti-obesity, anti-angiogenic capacities 
and also photoprotective (Chuyen & Eun, 2017; D’Orazio et al., 2012; 
Gao & McKinley, 1994; Heo et al., 2008; Heo & Jeon, 2009; Kotake-Nara 
et al., 2015; Kumar et al., 2013; Maoka et al., 2007; Mikami & Hoso-
kawa, 2013; Sugawara et al., 2009). However, to date, the most studied 
and researched bioactivity remains to be the antioxidant which is 
regarded for its beneficial effects on health for potential new applica-
tions in the food sector and the pharmaceutical industry (Kim & Pan-
gestuti, 2011; Muradian et al., 2015). Even though the possible 
applications for this pigment are very promising, they are limited 
because the commercialization of fucoxanthin is almost non-existent 
(Kanazawa et al., 2008). Indeed, the production of fucoxanthin has to 
face several challenges since its chemical synthesis represents a complex 
process that is not efficient and the extraction method from marine or-
ganisms has been not standardized (Kanda et al., 2014; Yamamoto et al., 
2011). As discussed below, there are very different extractive techniques 
that have been used for pigment extraction, such as the traditional 
heat-assisted extraction (maceration)(Shannon & Abu-Ghannam, 2017). 
For a product to be profitable, it is necessary to obtain it by using simple, 
fast and based on low-cost technologies (Raguraman et al., 2018), thus 
future and innovative studies regarding extraction methods can be of 
great help in the progress towards its commercialization (López et al., 
2018). 
Thus, even though carotenoids may be artificially synthesized, 
following laboratory protocols, their extraction from algae presents 
many more advantages. In the specific case of fucoxanthin, the acces-
sibility to the natural producers, mostly algae, convert this pigment in an 
economic and ecological alternative that provides a natural ingredient 
avoiding the safety issues prompted using chemical compounds. How-
ever, the extraction yield of fucoxanthin has been found to be very 
variable depending on the selected species and the recovery technique. 
Therefore, the main aim of this work is to underline the best algae in 
terms of fucoxanthin production and the most promising extraction and 
purification methods, while offering a complete panorama of the 
described bioactivities of fucoxanthin which includes bioavailability, 
administration via, doses and stability of the molecule. 
1.1. Principal matrices 
The first time that fucoxanthin was isolated was in 1914 in Germany 
from brown seaweeds (Phaeophyceae) Dictyota, Fucus, and Laminaria 
(Willstatter & Page, 1914). However, since that moment the presence of 
this carotenoid has been detected in many other macroalgae genera such 
as Alaria, Ascophyllum, Carpophyllum, Cladosiphon, Cystophora, Cystoseira 
Dictyota, Ecklonia, Ectocarpus, Eisenia, Fucus, Himanthalia, Hizikia, Ishige, 
Kjellmaniella, Laminaria, Myagropsis, Padina, Pelvetia, Petalonia, Saccha-
rina, Sargassum, Schytosiphon, Sporochnus, Turbinaria, and Undaria 
(Muradian et al., 2015). From these wide varieties of genera, currently, 
the alga species mostly used for the extraction of the fucoxanthin is 
Undaria pinnatifida (wakame) due to its high content can reach 10% in 
the lipid fraction (Billakanti et al., 2013). Nevertheless, unicellular 
microalgae have been found to synthesize fucoxanthin, besides, they are 
considered very efficient producer organisms since they can be easily 
and economically cultured to yield high concentrations of different 
biomolecules, such as pigments among others. The production of fuco-
xanthin has been studied mostly in diatoms (Bacillariophyceae) 
including Phaeodactylum tricornutum, Chaetoceros sp., Cylindrotheca 
closterium, and Odontella aurita (Peng et al., 2011). 
Fucoxanthin is a pigment mostly associated with brown algae even 
though its presence has been reported as a minor carotenoid in other 
algae groups such as Chlorophytes. Fucoxanthin is a not typical carot-
enoid from Chlorophytes however two different biosynthetic pathways 
for the metabolism of fucoxanthin in brown algae have been suggested 
to happen based on the conversion of β-carotene in fucoxanthin with 
diadinoxanthin and neoxanthin as precursors. Along these pathways, 
some carotenogenic genes have been identified, which are shared by 
both brown and green algae. However, the presence of fucoxanthin in 
green algae may be due to the biotransformation of different caroten-
oids, and this process is still not completely clear (Mikami & Hosokawa, 
2013). The presence of fucoxanthin in green algae has been reported in a 
study that used supercritical fluid extraction, with ethanol as co-solvent, 
as a tool to obtain extracts from freshwater green macroalgae which 
naturally occur in inland waters in Poland (Table 2). Extracts from 
Cladophora glomerata, and Chara fragilis, two of the studied species, 
among others were analyzed trough HPLC-DAD-MS allowing the 
tentative assignment of diverse carotenoids including fucoxanthin, 
especially in C. glomerata extracts (Fabrowska et al., 2016). 
The presence of fucoxanthin has been reported several times in the 
Rhodophyceae family but on several occasions, it was attributed to the 
presence of biological contaminants, like diatoms and Chrysophyceae 
mixed with the red algae. In a few cases, natural red algae compared 
with cultured ones showed that fucoxanthin was not produced by the 
algae themselves (Palermo et al., 1991). These analyses permit to 
eliminate the fucoxanthin contributions from biological contaminates, 
particularly microalgae and brown algae, by comparing naturally 
occurring red algae with cultured ones assuring that fucoxanthin and 
other carotenoids were in fact produced by the studied red algae 
analyzed (Bjørnland & Aguilar-Martinez, 1976). In additional 
Extraction techniques 
ME Maceration extraction 
EAE Enzyme-assisted extraction 
MAE Microwave-assisted extraction 
PLE Pressurized liquid extraction 
SFE Supercritical fluid extraction  
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microscopic studies the examination of three different red algae, Cor-
allina officinalis, Corallina elongata and Jania sp. did not show the pres-
ence of diatoms or other contaminants that could be responsible for the 
fucoxanthin yields detected (Table 2). Despite these results, the origin of 
fucoxanthin in red algae is still not certain, because its production by a 
microscopic symbiotic organism cannot be ruled out, so more studies 
with Rhodophyceae are necessary (Palermo et al., 1991). 
Brown algae, also known as Phaeophyceae, are responsible for the 
biggest fucoxanthin production, with this pigment being their major 
carotenoid. Fucoxanthin is synthesized through the xanthophyll-cycle 
pathway that converts zeaxanthin in fucoxanthin via antheraxanthin, 
violaxanthin, and diadionoxanthin; and usually, algae that possess this 
cycle are able to produce fucoxanthin (Terasaki et al., 2009). The con-
centration of this compound has been shown to be very variable when 
testing not only different species but also when the same species have 
been grown under different environmental conditions and seasonal 
changes (Fariman et al., 2016). 
The duration of sunshine, PAR (photosynthetically active solar ra-
diation), and seawater temperature were studied to determine the ef-
fects of these parameters. Results displayed that higher concentrations 
of fucoxanthin were detected between January and March (wintertime) 
where the sunlight hours were less, and the water temperature reaches 
the lowest values (Terasaki et al., 2009). Another work also evaluated 
how seasonal variations, and additionally geographical distributions, 
affected to the fucoxanthin content in two brown algae, Sargassum 
horneri and Cystoseira hakodatensis. The algae were collected in different 
locations but were lately cultivated in the same place. Regarding the 
geographical distribution, identical species collected from distant areas 
700 km from each other displayed different fucoxanthin concentrations. 
Thus, the authors suggested that genetic variation from different origins 
may be responsible for the fucoxanthin amount variability. Regarding 
seasonal changes, fucoxanthin concentrations started to increase in 
October reaching a maximum in January in both species with a 15% 
increase in winter months (Nomura et al., 2013). Therefore, from these 
studies, it can be deduced that the low light in winter months and lower 
water temperatures lead to an increase in fucoxanthin production in 
brown algae. 
On a similar note, the Sargassum fusiforme’s biological composition 
was tested while changing environmental factors that affect growth and 
biochemical composition, like temperature and salinity. The best fuco-
xanthin content was obtained at 15 ◦C and 10 psi at a maximum of 2.62 
mg/g (Table 2) (Li et al., 2019). 
Even though, Undaria pinnatifida is another brown alga well-known 
to possess high contents in fucoxanthin, with values that reach up to 
4.96 mg/g (Table 2) (Fung et al., 2013), some additional studies were 
able to extract even higher concentrations (Rajauria et al., 2017b). 
evaluated Himanthalia elongata as a potential source for dietary fuco-
xanthin and used low polarity solvents like n-hexane, diethyl ether, and 
chloroform to perform the extractions. The crude extract was then pu-
rified with preparative thin layer chromatography (P-TLC) and the 
identification, quantification and structure elucidation were elucidated 
trough LC-DAD-MS and NMR (1H and 13C). The purification step led to a 
yielded of 18.6 mg/g of fucoxanthin (Table 2) with a purity of 97% 
(Rajauria et al., 2017b). 
Another significant source of fucoxanthin is the group of the 
microalgae, some species, like the Bacillariophycean Odontella auritais is 
capable of producing more than 18 mg/g DW of this compound (Xia 
et al., 2013). Another Bacillariophycean, Chaetoceros calcitrans is a very 
important marine species because they are the base of the marine food 
chain. Fucoxanthin is the major light-harvesting complex in these 
microalgae, contributing to more than 10% of the estimated total pro-
duction of carotenoids in nature. The detected amounts of fucoxanthin 
in this species are around 5 mg/g of DW (Table 2) (Foo et al., 2015, 
2017). The main advantage of using microalgae as a source of fuco-
xanthin is that they can be cultured and grown in close photobioreactors 
providing an available, stable and sustainable supply of biomass all year 
round (Foo et al., 2015). Besides, as microalgae can grow in photo-
bioreactors, its growing conditions can be optimized for maximizing the 
extraction yield of a specific compound. In (McClure et al., 2018) they 
studied the effect of different culture conditions, light intensity, carbon 
dioxide addition and medium composition, on the production of fuco-
xanthin by Phaeodactylum tricornutum. They found that on day 7 of the 
cultivation, the fucoxanthin production was around 42.8 mg/g of 
biomass at low light conditions (100 μmol photons m− 2s− 1) and an in-
crease in light intensity resulted in a significant decrease in fucoxanthin 
production to only 9.9 mg/g. The effect of carbon dioxide addition did 
not affect significantly the cell growth rate or the fucoxanthin produc-
tion but the supplementation of the medium with nitrate increased the 
fucoxanthin levels on day 7 up to 57.4 mg/g (Table 2) (McClure et al., 
2018). 
Table 2 compiles an extended list of matrices in which fucoxanthin 
has been detected at different concentrations, as well as the respective 
extraction and detection methods used. 
1.2. Fucoxanthin metabolites 
Fucoxanthin represents one of the major accessory pigments found in 
the chloroplasts of the brown algae, together with chlorophyll a and c, 
and β-carotene. The chemical structure of the fucoxanthin is a carotene 
backbone oxygenated under the shape of different functional groups 
such as epoxy, hydroxyl, carbonyl and carboxyl moieties, besides it in-
cludes an allenic bond which reinforces the uniqueness of this molecule 
(Fig. 1A) (Peng et al., 2011). This singular pigment that provides the 
characteristic brown or olive-green color to the Phaeophyceae absorbs 
light in the blue-green to yellow-green part of the visible spectrum, 
mostly in the range of 450–540 nm. It behaves as a primary 
light-harvesting carotenoid that transfers energy to chlorophyll-protein 
complexes. Fucoxanthin exhibits high energy transfer efficiency that is 
thought to be related to the unique structure of this carotenoid (Kaji-
kawa et al., 2012). Some characteristics and physical properties of 
fucoxanthin are resumed in Table 1 (see Fig. 2). 
The presence of different fucoxanthin metabolites has been evident, 
and mostly, detected in plasma, liver, or adipose tissue depending on the 
species selected for the in vivo assay, the absence/presence of induced 
pathologies on these experimental models, the duration of the assay and 
the concentration of the fucoxanthin administrated. The wide variability 
observed along the published studies hinders their full comparison. 
However, general results can be extracted from the bioavailability and 
metabolism of these works. In vivo studies performed in mice and rats 
have demonstrated that fucoxanthin, after its oral administration, suf-
fers different chemical modifications, catalyzed by the specific enzymes 
of each target organ. The gastrointestinal hydrolysis of fucoxanthin 
seems to take place for 2 h, so in that period, it would be likely to detect 
it in the plasma or the liver in mice (Asai et al., 2004; Matsumoto et al., 
2010). A study performed with the cell line named CaCO-2, used as an 
intestinal epithelium barrier model to evaluate intestinal absorption 
rates, showed that fucoxanthin become fucoxanthinol (Fig. 1B) (Suga-
wara et al., 2002, 2009). Based on different animal models, this 
biotransformation has been suggested to be mediated by lipases or es-
terases that trigger its hydrolysis and it has been proven to occur after 
the administration of fucoxanthin in different species such as hens, mice 
or rats (Asai et al., 2004; Sangeetha et al., 2010; Strand et al., 1998; 
Sugawara et al., 2002). Once deacetylated, fucoxanthin becomes into a 
non-polar molecule of greater bioavailability ready to be incorporated 
into chylomicrons that permit to fucoxanthinol to reach different sys-
temic organs, mainly the liver, lungs, kidney, heart, and spleen (Kota-
ke-Nara et al., 2015; Sugawara et al., 2002, 2009). Whereas, in other 
organs, fucoxanthin, already transformed in fucoxanthinol, seems to be 
rapidly metabolized by the action of a short-chain reductase or dehy-
drogenase to be converted into another metabolite known as amar-
ouciaxanthin A (Fig. 1C). Studies based on the use of hepatic cells 
(HepG2) demonstrated that fucoxanthinol becomes into 
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amarouciaxanthin A (Fig. 1C) by a dehydrogenation/isomerization. This 
step is probably catalyzed by a NAD(P)+-dependent dehydrogenase and 
it was predominantly shown in liver microsomes (Asai et al., 2004). As 
in the case of the fucoxanthinol, amarouciaxanthin A also reaches blood 
circulation and additional targets, primarily the adipose tissue (Hashi-
moto et al., 2009; Peng et al., 2011; Yonekura et al., 2010). In fact, when 
animals were fed for periods longer than a week, fucoxanthin and its 
metabolites were detected in blood and other organs or tissues apart 
from those considered as principals (Hashimoto et al., 2009; Yonekura 
et al., 2010). In the case of hens fed with Fucus serratus fucoxanthinol 
reach the egg yolk being the major carotenoid identified (Strand et al., 
1998). 
Apart from tested in animal models, fucoxanthin was also 
administrated to humans in different experiments where its metabo-
lization was evaluated. One of the experiments consisted of the admin-
istration of a concentration of 6.1 mg of fucoxanthin (extracted from 
wakame) for a week while the other one provided a unique dose of 31 
mg of fucoxanthin (obtained from Kombu). Fucoxanthinol was detected 
on blood tests in both experiments, in fact in the latter assay displayed 
higher relative amounts of fucoxanthinol in humans than in animals 
whereas amarouciaxanthin A was absent (Asai et al., 2008; Hashimoto 
et al., 2012). But an interesting observation was provided by the second 
assay where human data was compared against the results obtained for 
mice. They concluded that the administrated dose for humans was seven 
times lower while the fucoxanthinol concentration in plasma was just a 
third or a half of that in mice. Data obtained from other experiments 
Fig. 1. Chemical representation of a) fucoxanthin, b) fucoxanthinol, c) amaroucianxanthin A and d) halocynthiaxanthin.  
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yielded similar results, showing that a dietary supplement of 0.024 mg 
of fucoxanthin per kilo and per day was enough to reduce abdominal 
WAT in humans (Abidov et al., 2010) while for achieving the same re-
sults in obese mice a dose higher than 100 mg of fucoxanthin per kilo 
and per day was required administrated (Airanthi et al., 2011; Maeda 
et al., 2009). The lower concentration of fucoxanthin or fucoxanthinol 
detected or the high doses needed for having effects on mice may be due 
to the faster metabolism of small and short-lived animals as well as to the 
differential fucoxanthin-like molecules absorption rates of each species 
(Mordenti, 1986). Instead, the lack of arouciaxanthin A in human 
plasma may be owed to the lack of information about the metabolic 
pathway that fucoxanthin follows in different organs which may hinder 
the quantification of the final metabolic compounds. As far as scientific 
works get published additional metabolites of fucoxanthin are disclosed. 
This is the case of a study in which besides fucoxanthinol, hal-
ocynthiaxanthin have been isolated from U. pinnatifida (Fig. 1D) 
(Sachindra et al., 2007). Many factors remain to be studied in the 
metabolism of the fucoxanthin, thus the research on the metabolic 
pathway of fucoxanthin and the study of these compounds is really 
interesting since it has been proved that, at least, fucoxanthinol can 
produce even greater functional effects than fucoxanthin (Sun et al., 
2019). 
2. Extraction methods 
The development of fucoxanthin extraction techniques with high- 
efficiency rates is one of the main goals of the industry involved in the 
production of natural pigments. 
The most common technique for obtaining fucoxanthin is through 
maceration extraction (ME, Table 2). Maceration consists of a solid/ 
liquid extraction in which different variables are evaluated: biomass- 
solvent ratio, type, and percentage of solvent, or time and temperature 
of incubation. Usually, these parameters need to be optimized under 
different combinations for which is useful a response surface method-
ology (RSM) (Pinela et al., 2019). Temperatures and times of extraction 
tested for fucoxanthin were very variable (from 4 ◦C up to 65 ◦C, during 
15 min–96 h) and solvents too (methanol, acetone, and ethanol, being 
the most commons) (Table 2). Among the scientific literature reviewed 
the best yield result obtained with ME for macroalgae has been 
accomplished with Himanthalia elongata using equal volumes of n-hex-
ane, diethyl ether, and chloroform (18.6 mg/g DW) (Rajauria and 
Abu-Ghannam, 2017). Whereas the maximum yield in microalgae was 
obtained with Phaeodactylum tricornutum and ethanol (57.4 mg/g DW) 
however, in this experiment the main key was the modification of the 
growing parameters (McClure et al., 2018) (Table 2). Other innovative 
techniques imply the use of expensive instruments or reagents such as 
for enzyme-assisted extraction (EAE), microwave-assisted extraction 
(MAE), pressurized liquid extraction (PLE), or supercritical fluid 
extraction (SFE). EAE permits to hydrolyze cellulose walls to facilitate 
the exit of the pigment from the cell A study using Fucus vesiculosus 
showed that the best conditions were enzyme-to-water ratio 0.52%, 
seaweed-to-water ratio 5.37% and enzyme incubation time 3 h 
Table 1 












Density: 1.1 ± 0.1 g/cm3 
Boiling Point: 764.1 ± 60.0 ◦C at 760 mmHg 
Flash Point: 223.0 ± 26.4 ◦C  
Fig. 2. The main sources of fucoxanthin are brown algae (Phaeophytes) and some microalgae. Several techniques have been employed to extract this compound, 
such as maceration extraction (ME), enzyme assisted extraction (EAE), microwave assisted extraction (MAE), pressurized liquid extraction (PLE) or supercritical fluid 
extraction (SFE). Following the extraction, the identification step has been carried out using different chromatographic and spectroscopic techniques. Fucoxanthin 
has gained attention in the last decades, due to the wide variety of attributed beneficial activities, such as antioxidant, anti-inflammatory, anticancer or neuro-
protective effects. These bioactivities are interesting for its diverse applications in the industry, including the development of innovative pharmaceutical, cosmetic 
and food products. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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Table 2 
Algae species described as source of fucoxanthin, solvent used for specific extraction techniques, detection methods employed for determining its presence and 
quantification values (fucoxanthin concentration are expressed in mg/g of dry weight, DW, or where not detected, nd, was indicated).  
ALGAE SPECIE SOLVENT EXTRACTION 
METHOD 




Chara fragilis EtOH SFE HPLC-DAD–MS nd Fabrowska et al. (2016)  
Cladophora glomerata EtOH SFE HPLC-DAD–MS nd Fabrowska et al. (2016) 
Red  
Corallina officinalis DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.04 Palermo et al. (1991)  
Corallina elongata DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.02 Palermo et al. (1991)  
Euchema cottoni EtOH ME HPTLC 0.94 Agatonovic-Kustrin et al. (2018)  
Jania sp. DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.08 Palermo et al. (1991) 
Brown  
Alaria crassifolia MeOH ME (RT, 12h) HPLC-PDA 1.1 Terasaki et al. (2009)  
Alaria esculenta AcO 62.2% ME (30◦, 36.5 min) HPLC-DAD 0.87 Shannon and Abu-Ghannam (2017)  
Analipus japonicas MeOH ME (RT, 12h) HPLC-PDA 1.40 Terasaki et al. (2009)  
Ascophylum nodossum EtOH VAE HPLC-PDA 0.022 (Nunes et al., 2019)  
Cladosiphon 
okamuranus 
MeOH ME (RT, 1h) HPLC-DAD 0.27 (Mise, Ueda, & Yasumoto, 2011)  
Corallina elongate DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.02 Palermo et al. (1991)  
Corallina officinalis DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.04 Palermo et al. (1991)  
Cystoseira hakodatensis Ch, MeOH ME HPLC-DAD 2.01 (Susanto, Fahmi, Abe, Hosokawa, & 
Miyashita, 2016)  
Cystoseira Hakodatensis Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 2.01 (Susanto et al., 2016)  
Cystoseira hakodatensis MeOH ME (RT, 12h) HPLC-PDA 2.40 Terasaki et al. (2009)  
Cystoseira hakodatensis Ch/MeOH (1:2) ME (RT, 1h) HPLC-DAD 3.47 Nomura et al. (2013)  
Desmarestia viridis MeOH ME (RT, 12h) HPLC-PDA 0.10 Terasaki et al. (2009)  
Dictyopteris australis AcO ME (4 ◦C, 12h) Spec 0.23 (Verma, Kumar, Mishra, & Sahoo, 2017)  
Dictyota dichotoma EtOH ME HPTLC 0.44 ()  
Dictyota dichotoma EtOH VAE HPLC-PDA 0.60 (Nunes et al., 2019)  
Dictyota dicotoma AcO ME (4 ◦C, 12h) Spec 0.18 (Verma et al., 2017)  
Dictyota dicotoma MeOH ME (RT, 24h) HPLC-PDA 6.42 (S. J. Heo et al., 2010)  
Ecklonia kurome Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 1.68 (Susanto et al., 2016)  
Eisenia bicyclis EtOH PLE HPLC-PDA 0.42 Shang et al. (2011)  
Euchema cottoni EtOH ME HPTLC 0.94 Agatonovic-Kustrin et al. (2018)  
Fucus distichus MeOH ME (RT, 12h) HPLC-PDA 0.90 Terasaki et al. (2009)  
Fucus distichus AcO ME Spec 0.16 (Seely, Duncan, & Vidaver, 1972)  
Fucus serratus EtOH SFE HPLC-DAD 2.18 (Heffernan et al., 2016b)  
Fucus serratus Hx/AcO (70:30) ME HPLC-DAD 3.57 (Heffernan et al., 2016b)  
Fucus vesiculosus EtOH VAE HPLC-PDA 0.02 (Nunes et al., 2019)  
Fucus vesiculosus AcO VAE HPLC-DAD 0.70 Shannon and Abu-Ghannam (2017)  
Fucus vesiculosus W EAE HPLC-UV, LC-MS 0.66 Shannon and Abu-Ghannam (2018)  
Himanthalia elongata n-Hx, DE, Ch ME LC-MS, HPLC, 1H NMR 18.60 (Rajauria et al., 2017)  
Hizikia fusiformis MeOH ME HPLC-DAD 0.02 Kanazawa et al. (2008)  
Ishige okamurae MeOH ME HPLC-DAD nd (Kanda et al., 2014)  
Iyengaria stellate AcO ME (4 ◦C, 12h) Spec 0.18 (Verma et al., 2017)  
Jania sp. DCM ME (RT) HPLC, 1H NMR, 
13C NMR 
0.08 Palermo et al. (1991)  
Kjellmaniella crassifolia MeOH ME (RT, 15 min) HPLC-DAD 0.15 Foo et al. (2017)  
Laminalia japonica MeOH ME HPLC-DAD 0.19 Kanazawa et al. (2008)  
Laminaria digitata AcO 62.2% ME (30◦, 36.5 min) HPLC-DAD 0.65 Shannon and Abu-Ghannam (2017)  
Laminaria japonica Hp, AcO, W MAE LC-MS, HPLC, 1H NMR 0.04 Xiao et al. (2012)  
Laminaria religiosa MeOH ME (RT, 96h) HPLC-DAD, 1H NMR, 13C 
NMR 
0.24 (Mori et al., 2004)  
Laminaria saccharina AcO ME Spec 0.24 (Seely et al., 1972)  
Leathesia difformis MeOH ME (RT, 12h) HPLC-PDA 0.30 Terasaki et al. (2009)  
Lobophora variegata AcO ME (4 ◦C, 12h) Spec 0.23 (Verma et al., 2017)  
Melanosiphon intestinalis MeOH ME (RT, 12h) HPLC-PDA 1.90 Terasaki et al. (2009)  
Myagropsis myagroides MeOH ME (RT, 24h) HPLC-PDA 9.01 (S. J. Heo et al., 2010)  
Padina australis Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 1.29 (Susanto et al., 2016)  
Padina gymnospora AcO ME (4 ◦C, 12h) Spec 0.44 (Verma et al., 2017)  
Padina minor EtOH ME HPTLC 0.50 Agatonovic-Kustrin et al. (2018)  
Padina pavonica EtOH ME HPTLC 0.43 Agatonovic-Kustrin et al. (2018)  
Padina tetrastromatica AcO ME (4 ◦C, 12h) Spec 0.41 (Verma et al., 2017)  
Padina tetrastromatica EtOH UAE HPLC-DAD 0.75 (Raguraman et al., 2018b)  
Petalonia binghamiae MeOH ME (RT, 48h) HPLC-DAD, 1H NMR, 13C 
NMR 
0.59 (Mori et al., 2004)  
Saccharina japonica MeOH ME (RT, 15 min) HPLC-DAD 0.07 Foo et al. (2017)  
Saccharina japonica n-Hx SAE (40 ◦C, 16h) HPLC-DAD 0.45   
Saccharina sculpera MeOH ME (RT, 12h) HPLC-PDA 0.70 Terasaki et al. (2009) 
(continued on next page) 
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Table 2 (continued ) 
ALGAE SPECIE SOLVENT EXTRACTION 
METHOD 
DETECTION METHOD FUCOXANTHIN REFERENCE 
(mg/g DW)  
Sargassum binderi MeOH ME (RT, 12h x2) HPLC-DAD 0.73 Jaswir, Noviendri, Salleh, & Miyashita 
(2012)  
Sargassum confusum MeOH ME (RT, 12h) HPLC-PDA 1.60 Terasaki et al. (2009)  
Sargassum crassifolium Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 1.64 (Susanto et al., 2016)  
Sargassum duplicatum MeOH ME (RT, 12h x2) HPLC-DAD 1.01 (Jaswir et al., 2012)  
Sargassum fulvellum MeOH ME HPLC-DAD 0.01* Kanazawa et al. (2008)  
Sargassum fusiforme MeOH ME (RT, 12h) HPLC-PDA 1.10 Terasaki et al. (2009)  
Sargassum fusiforme AcO/EtOH (1:40) ME (65 ◦C, 80 min) Spec 2.62 (J. Li et al., 2019)  
Sargassum fusiforme Hp, AcO, W MAE LC-MS, HPLC, 1H NMR 0.02 Xiao et al. (2012)  
Sargassum horneri Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 2.12 (Susanto et al., 2016)  
Sargassum horneri MeOH ME (RT, 12h) HPLC-PDA 3.70 Terasaki et al. (2009)  
Sargassum horneri Ch/MeOH (1:2) ME (RT, 1h) HPLC-DAD 4.49 Nomura et al. (2013)  
Sargassum horneri CO2, EtOH SFE (45◦ , 250 bar) HPLC-DAD 0.77 Sivagnanam et al. (2015)  
Sargassum japonica CO2, EtOH SFE (45◦ , 250 bar) HPLC-DAD 0.41 Sivagnanam et al. (2015)  
Sargassum linearifolium AcO ME (4 ◦C, 12h) Spec 0.38 (Verma et al., 2017)  
Sargassum muticum AcO ME Spec 0.29 (Seely et al., 1972)  
Sargassum 
plagiophyllum 
AcO/MeOH (7:3) ME (ice, 15 min) HPLC 0.71 (Jaswir et al., 2013)  
Sargassum polycystum EtOH ME HPTLC 0.41 Agatonovic-Kustrin et al., 2018  
Sargassum siliquastrum Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 1.99 (Susanto et al., 2016)  
Sargassum thunbergii MeOH ME (RT, 12h) HPLC-PDA 1.80 Terasaki et al. (2009)  
Sargassum vulgare EtOH VAE HPLC-PDA 0.40 (Nunes et al., 2019)  
Scytosiphon lomentaria MeOH ME (RT, 12h) HPLC-PDA 0.50 Terasaki et al. (2009)  
Scytosiphon lomentaria MeOH ME (RT, 96h) HPLC-DAD, 1H NMR, 13C 
NMR 
0.56 (Mori et al., 2004)  
Silvetia babingtonii MeOH ME (RT, 12h) HPLC-PDA 0.70 Terasaki et al. (2009)  
Spatoglossum asperum AcO ME (4 ◦C, 12h) Spec 0.58 (Verma et al., 2017)  
Sphaerotrichia 
divaricata 
MeOH ME (RT, 12h) HPLC-PDA 0.20 Terasaki et al. (2009)  
Stoechospermum 
marginatum 
AcO ME (4 ◦C, 12h) Spec 0.37 (Verma et al., 2017)  
Turbinaria ornata Ch/MeOH (1:2) ME (RT, 2h) HPLC-DAD 1.27 (Susanto et al., 2016)  
Turbinaria spp. AcO ME (4 ◦C, 12h) Spec 0.43 (Verma et al., 2017)  
Turbinaria turbinata AcO/MeOH (7:3) ME (ice, 15 min) HPLC 0.59 (Jaswir et al., 2013)  
Undaria pinnatifida MeOH ME (RT, 96h) HPLC-DAD, 1H NMR, 13C 
NMR 
2.67 (Mori et al., 2004)  
Undaria pinnatifida Hp, AcO, W MAE LC-MS, HPLC, 1H NMR 0.90 Xiao et al. (2012)  
Undaria pinnatifida MeOH ME (RT, 1h) HPLC-DAD 2.08 Fung et al. (2013)  
Undaria pinnatifida MeOH ME (RT, 1h) HPLC-DAD 4.96* Fung et al. (2013)  
Undaria pinnatifida EtOH ME (RT, 1h) HPLC-DAD 0.07* Billakanti et al. (2013)  
Undaria pinnatifida EtOH ME (RT, 1h) HPLC-DAD 0.70 Billakanti et al. (2013)  
Undaria pinnatifida CO2, EtOH SFE (50◦ , 200 bar) HPLC-UV >0.01 (Roh et al., 2008)  
Undaria pinnatifida CO2, EtOH SFE (60◦ , 400 bar) HPLC-UV 0.99 Kanda et al. (2014)  
Undaria pinnatifida EtOH PLE (12h, 78◦) HPLC-UV 0.05 Kanda et al. (2014)  
Zonaria tournefortii EtOH VAE HPLC-PDA 0.80 (Nunes et al., 2019) 
MICROALGAE  
Amphora sp. AcO ME (ice) HPLC-PDA 1.21** (Ishika et al., 2017)  
Chaetoceros calcitrans DE UAE HPLC-DAD 4.49 Foo et al. (2015)  
Chaetoceros calcitrans DCM UAE HPLC-DAD 5.25 Foo et al. (2015)  
Chaetoceros calcitrans MeOH ME (RT, 15 min) HPLC-DAD 5.13 Foo et al. (2017)  
Chaetoceros gracilis EtOH ME (RT, 1h) HPLC-DAD 2.24 (S. M. Kim, Kang, Kwon, Chung, & Pan, 
2012) 
1.1.1. Chaetoceros muelleri AcO ME (ice) HPLC-PDA 2.92** (Ishika et al., 2017)  
Chrysotila carterae AcO ME (ice) HPLC-PDA 1.04** (Ishika et al., 2017)  
Cylindrotheca closterium AcO MAE HPLC 4.24 (Pasquet et al., 2011)  
Isochrysis aff. galbana EtOH ME (RT, 1h) HPLC-DAD 18.23 (S. M. Kim, Kang, et al., 2012)  
Isochrysis galbana EtOH ME (RT, 1h) HPLC-DAD 6.04 (S. M. Kim, Kang, et al., 2012)  
Isochrysis galbana MeOH ME (RT, 15 min) HPLC-DAD 2.19 Foo et al. (2017)  
Mallomonas sp. Ch, MeOH, EtOH, 
AcON 
ME (RT, 20 min) HPLC-DAD 26.60 (Petrushkina et al., 2017)  
Navicula- sp. AcO ME (ice) HPLC-PDA 1.49** (Ishika et al., 2017)  
Nitzschia sp. EtOH ME (RT, 1h) HPLC-DAD 4.92 (S. M. Kim, Kang, et al., 2012)  
Odontella aurita EtOH ME (RT, 1h) LC-DAD-MS 18.47 Xia et al. (2013)  
Odontella sinensis MeOH ME (RT, 15 min) HPLC-DAD 1.18 Foo et al. (2017)  
Phaeodactylum 
tricornutum 
EtOH ME (45 ◦C, 2h) HPLC 3.51 (F. L. Li et al., 2018)  
Phaeodactylum 
tricornutum 
EtOH ME (RT, 1h) HPLC-DAD 8.55 (S. M. Kim, Kang, et al., 2012)  
Phaeodactylum 
tricornutum 
EtOH ME HPLC-PDA 57.40 McClure et al. (2018)  
Phaeodactylum 
tricornutum 
EtOH ME (RT, 30 min) HPLC-UV, LC-MS, 1H NMR, 
13C NMR 
15.71 (S. M. Kim, Jung, et al., 2012)  
Pheodactylum 
tricornutum 
AcO ME (ice) HPLC-PDA 1.87** (Ishika et al., 2017) 
(continued on next page) 
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(Shannon & Abu-Ghannam, 2018).MAE applied for recovering fuco-
xanthin has been revealed a great approach in a study carried out using 
different solvents in Laminaria japonica, Undaria pinnatifida, and 
Sargassum fusiforme. The optimized parameters (solvent:sample ratio of 
10:1 mL/g, 50 ◦C,10 min) provided high extraction efficiencies: 5, 109, 
and 2 mg/100 g, respectively (Xiao et al., 2012). The application of PLE 
for Undaria pinnatifida using Soxhlet with ethanol (78 ◦C, 12h) yielded of 
50 μg/g DW of fucoxanthin (Kanda et al., 2014) while when applied to 
Eisenia bicyclis (110 ◦C, 90% ethanol, 5 min) using an accelerated solvent 
extractor the efficiency increased nearly 10 times with a yield of 0.42 mg 
of fucoxanthin/g DW (Shang et al., 2011). For SFE applied for fuco-
xanthin extraction the mostly used solvent is CO2 with ethanol as 
entrainer to improve the method efficiency. ASFE-based work compared 
the application of CO2 and CO2+ethanol for Undaria pinnatifida. The 
optimized method (70 ◦C,400 bar, 3 h) using just CO2 achieved a 
fucoxanthin yield of 60.12 μg/g. Whereas the method based in the 
co-elution of ethanol as entrainer (60 ◦C, 400 bar, 3 h) reached an 
extraction efficiency 16 times higher (994.53 μg of fucoxanthin/g DW) 
(Kanda et al., 2014). SFE using just (45 ◦C, 250 bar, 2 h) was also tested 
in Saccharina japonica and Sargassum horneri and allowed the recovery or 
rich-fucoxanthin oil fractions with respective 0.41 ± 0.05 and 0.77 ±
0.07 mg/g DW (Sivagnanam et al., 2015). Thus, temperature, pressure, 
and co-solvent need to be set up to obtain the best results with SFE. 
As explained above, even though, the development of an optimized 
extraction procedure is essential to achieve a high-throughput, the cul-
ture conditions of algae are crucial (McClure et al., 2018). Additionally, 
the selection of an adequate quantification technique will provide more 
accurate results. The most utilized ones are the liquid chromatography 
mass spectrometry (LC-MS) for a mass-to-charge ratio (m/z)-based 
identification, high performance liquid chromatography (HPLC) 
coupled to ultraviolet (UV) or diode-array detector (DAD) for the 
identification based on a maximum absorbance peak at 446 nm or the 
nuclear magnetic resonance (NMR) for determining its structure (Xia 
et al., 2013). 
3. Biological activities 
In the last decades, numerous studies have reported the wide range 
of biological activities of fucoxanthin, such as radical scavenging, anti- 
inflammatory, anti-tumor, anti-obesity, neuroprotective, and many 
others as reported in Table 3 (Chuyen & Eun, 2017). 
3.1. Antioxidant activity 
The excellent antioxidant properties of fucoxanthin against oxidative 
stress have been confirmed throughout numerous studies. The unique 
chemical structure of fucoxanthin possesses an allenic bond and an 
acetyl functional group which are considered to be responsible for its 
antioxidant properties (Guvatova et al., 2020; Liu et al., 2011; Miyashita 
et al., 2020). Fucoxanthin has been shown to scavenge different free 
radicals, like DPPH, ABTS, hydrogen peroxide, hydroxyl radical, su-
peroxide anion and singlet oxygen, and also the 12-doxyl-stearic acid 
and nitrobenzene with linoleic acid (Liu et al., 2011; Ristivojević et al., 
2021). For DPPH, its radical scavenging activity may be quantified in 
terms of effective or inhibitory concentrations (EC or IC, respectively). 
The concentration required to obtain a 50% antioxidant effect (EC50) is 
often used to express the antioxidant capacity and allows the compari-
son among different compounds. Whereas the concentration of the 
sample required inhibiting 50% of DPPH radicals usually permits the 
comparison against other assays (Barros et al., 2011; Lopes et al., 2018). 
Fucoxanthin exhibited an EC50 for DPPH scavenging of 165 μM while its 
two derivative compounds, fucoxanthinol and halocynthiaxanthin, 
presented an EC50 of 154, and 826 μM, respectively (Sachindra et al., 
2007). A recent study estimated that fucoxanthin extracted from the 
diatom Phaeodactylum tricornutum, presented an IC50 of 201 μg/mL in 
DPPH assay. FRAP assay revealed that fucoxanthin is equal to 65 mmol 
Fe2+ per gram (Neumann et al., 2019). The antioxidant activity of 
fucoxanthin has been assessed in numerous studies in vitro using animal 
and human cell cultures. For animal cell lines the effect of fucoxanthin 
was tested in different tissue cells from diverse species, such as the 
kidney fibroblast cells from monkey (Vero), the murine hepatic cells 
from mouse (BNL CL.2) or the adipocytes from mouse (3 T3-L1). In 
kidney cells Vero, fucoxanthin isolated from Sargassum siliquastrum 
inhibited the oxidative damage caused by H2O2, reduced intracellular 
levels of reactive oxygen species (ROS), DNA fragmentation and 
apoptotic processes (Heo et al., 2008). Similar results were obtained 
when fucoxanthin (1–20 μM) was tested in hepatocyte cells, BNL CL.2, 
previously treated with ferric nitrilotriacetate, a compound described to 
cause apoptosis. In this assay, fucoxanthin reduced the production of 
intracellular ROS, DNA damage and increased the levels of glutathione, 
with an important role in the cellular defense against oxidants and the 
maintenance of the redox cell homeostasis highly related with the pre-
vention of apoptotic processes (Liu et al., 2011). Following this trend, 
fucoxanthin was demonstrated to inhibit lipid accumulation and ROS 
formation in 3 T3-L1 mouse adipocytes (Jang et al., 2018). Fucoxanthin 
also exhibited antioxidant effects on human cell lines with similar results 
than those observed for animal models. On fibroblasts irradiated with 
UVB, fucoxanthin protected cells from oxidative damage, reducing the 
levels of intracellular ROS and DNA damage in a dose-dependent 
manner (Jin Heo & Jeon, 2009; Wijesinghe & Jeon, 2011). The reduc-
tion on the production of intracellular ROS promoted by fucoxanthin 
isolated from Laminaria japonica (50 μg/mL) was also demonstrated in 
retinal pigment epithelium cells exposed to damage by excessive 
visible-light radiation, reaching almost normal levels and no cytotoxic 
effects (Liu et al., 2016). The same reduction on the oxidative damage, 
caused by H2O2, was produced when fucoxanthin (5 μM) was applied to 
Table 2 (continued ) 
ALGAE SPECIE SOLVENT EXTRACTION 
METHOD 
DETECTION METHOD FUCOXANTHIN REFERENCE 
(mg/g DW)  
Phaeodactylum 
tricornutum 
MeOH ME (RT, 15 min) HPLC-DAD 0.07 Foo et al. (2017)  
Skeletonema costatum MeOH ME (RT, 15 min) HPLC-DAD 0.36 Foo et al. (2017)  
Tisochrysis lutea AcO ME (ice) HPLC-PDA 2.05** (Ishika et al., 2017) 
Solvent: Ethanol (EtOH); Methanol (MeOH); Acetone (AcO); Chloroform (Ch); Hexane (Hx); Dichloromethane (DCM); Heptane (Hp); Water (W); n-Hexane (n-Hx); 
Diethyl ether (DE); Acetonitrile (AcN). 
Extraction method: Supercritical fluid extraction (SFE); Supercritical CO2 Extraction; Ultrasonic assisted extraction (UAE); Maceration extraction (ME); Pressurized 
liquid extraction (PLE); Microwaves assisted extraction (MAE); Vortex-assisted solid-liquid micro-extraction (VAE), Enzyme-assisted extraction (EAE), Soxhlet assisted 
extraction (SAE). 
Detection method: High Performance Liquid Chromatography (HPLC); HPLC with diode array detector (HPLC-DAD); HPLC with ultraviolet detector (HPLC-UV); 
HPLC-DAD coupled to Mass Spectrometry (HPLC-DAD–MS); Liquid Chromatography Mass Spectrometry (LC-MS); LC with DAD and MS (LC-DAD-MS); High Per-
formance Thin Layer Chromatography (HPTLC); Proton nuclear magnetic resonance (1H NMR); Carbon-13 nuclear magnetic resonance (13C NMR); Spectrophotometry 
(Spec). 
Fucoxanthin content: not determined: fucoxanthin was found but not quantified (nd); DW: Dry Weight; Fresh Wight (* FW); Ash Free Dry Wight (** AFDW). 
C. Lourenço-Lopes et al.                                                                                                                                                                                                                       
Trends in Food Science & Technology 117 (2021) 163–181
172
SH-SY5Y human neuroblastoma cells, primary cerebellar granule neu-
rons and human hepatic L02 cells (Wang, Park, et al., 2018a; Yu et al., 
2017). The antioxidant activity of fucoxanthin demonstrated in so 
different cell models has been related to the enhancement of the 
expression levels of the nuclear factor erythroid 2-related factor 2 
(Nrf2). The Nrf2 is a transcription factor related to the antioxidant 
mechanism, fundamental to protect the cell against oxidative damage. 
In the absence of cellular stress, Nrf2 is usually located in the cytoplasm 
and transcriptionally inactive. However, oxidative stress promotes its 
translocation to the nucleus which triggers the expression of 
stress-induced genes, such as those for the quinine oxidoreductase 1 
(NQO1) or the heme oxygenase-1 (HO-1), two cytoprotective enzymes 
which defend the cell against stress factors. Dietary ingredients with 
antioxidant capacity have been reported as potential cell protectors from 
oxidative damage by modulating the Nrf2 pathway (Tang et al., 2014, 
pp. 13079–13087; X.; Wang, Park, et al., 2018a). In fact, one of these 
dietary compounds is fucoxanthin since it has been described to produce 
its antioxidant effects by altering this Nrf2 pathway (X. Wang, Park, 
et al., 2018a). 
Finally, fucoxanthin has been found to present antioxidant effects in 
vivo very similar to those observed in vitro. The action of fucoxanthin was 
tested in animals with pathologies induced, such as the obese/diabetes 
KK-Ay mice model. The treatment with 0.2% of fucoxanthin decreased 
lipid peroxidation levels of liver and abdominal adipose tissue and 
reduced the oxidative damage associated with diabetes and obesity 
(Rokkaku et al., 2013). When evaluated in rats with retinol deficiency, 
the results showed the same effects for fucoxanthin (0.83 μM): it pro-
tected against oxidative stress by reducing the levels of lipid peroxida-
tion and increasing the activity of two antioxidant enzymes, catalase and 
glutathione transferase (Baskaran et al., 2009). Another pathology 
induced to rats administrating them diethylnitrosamine (DEN), the 
hepatocarcinogenesis, was treated with fucoxanthin. As demonstrated 
before, lower intracellular ROS levels and lipid peroxidation were 
detected for those rats feed with fucoxanthin. Besides lower liver stress 
markers were found and significant cellular antioxidant defenses were 
increased for fucoxanthin-fed rats (Jin et al., 2019). 
3.2. Cytoprotective effect 
Several studies have reported the protective effects of fucoxanthin in 
in vitro assays using different cell lines, in many cases related to its 
antioxidant properties, as previously exposed. The pre-treatment with 
fucoxanthin before exposing cells to different types of damage and stress 
has been demonstrated to restore the cell survival comparing to control 
cells. In different animal models, fucoxanthin displayed different pro-
tective routes against the damage that were caused by H2O2 or UVB 
prolonged radiation. In monkey kidney fibroblasts exposed to H2O2, the 
pre-treatment with fucoxanthin significantly increased in a dose- 
dependent manner the cell survival (Soo-Jin You-Jin et al., 2008). In 
the case of rat glioma cells treated with UVB, fucoxanthin supplemen-
tation before and after the UVB exposition increased significantly cell 
viability and reduced the DNA damage caused by the radiation and even 
Table 3 
Summary of fucoxanthin bioactivities and effects.     
ACTIVITIES MODEL REFERENCES 
Antioxidant DPPH, ABTS, hydrogen peroxide, 
hydroxyl radical, superoxide anion 
and singlet oxygen. 
(Liu et al., 2011;  
Wang, Park, et al., 
2018a) 
DPPH. Sachindra et al. 
(2007) 
FRAP assay. Neumann et al. (2019) 
Monkey kidney fibroblast cells 
(Vero). 
Heo et al. (2008) 
Inhibit lipid accumulation and 
ROS formation in vitro 3 T3-L1 
mouse adipocytes. 
Jang et al. (2018) 
SH-SY5Y human neuroblastoma 
cells, primary cerebellar granule 
neurons and human hepatic L02 
cells. 
(X. Wang, Park, et al., 
2018a; Yu et al., 
2017) 
Protected against oxidative stress 
by reducing the levels of lipid 
peroxidation and increasing the 
activity of catalase and glutathione 
transferase. 
Sangeetha, Bhaskar, & 
Baskaran (2009) 
Cytoprotective Human fibroblasts (S. J. Heo & Jeon, 
2009b) 
Human hepatic LO2 cell Wang, Park, et al. 
(2018b) 
Pre-treated in vitro Hep G2 human 
liver cancer cells 
Jang et al. (2018) 
Protected photoreceptor cells (rod 
cells and cone cells) on an in vivo 
rabbit model 
Liu et al. (2016) 
Anticancer Inhibit growth and induce 
apoptosis on B16-F10 melanoma, 
BNL CL.2 embryonic liver and 
Neuro2a neuroblastoma murine 
cell lines 
Chuyen and Eun 
(2017) 
GOTO, human colon carcinoma 
WiDr, HepG2, Burkitt’s and 
Hodgkin’s lymphoma and T-cell 
leukemia cells 
Satomi (2017) 
Caco-2, HT-29, DLD-1 Hosokawa et al. 
(2004) 
Human cervical cancer SiHa cells (Y. Jin et al., 2018) 
Anti-inflammatory Inhibiting inducible nitric oxide 
synthase (iNOS) and 
cyclooxygenase 2 (COX-2) protein 
expression 
(S. Heo et al., 2010) 
Inhibition of mRNA expressions of 
interleukin-6, plasminogen 
activator inhibitor-1 (PAI-1), COX- 
2 and iNOS in Raw 264.7 
macrophages co-cultures, and in 3 
T3-L1 adipocyte cells 
(L. Wang, Park, et al., 
2018a) 
Antiobesity Obese mice and rats Okada et al. (2008) 
Neuroprotective Inhibition in the expression of N- 
myc, a proto-oncogene protein, as 
well as proliferation of GOT0 cells 
Okuzumi et al. (1990) 
Activation of Nrf2 and its target 
genes 
Hu et al. (2018) 
Nrf2-ARE and Nrf2-autophagy 
pathways in in vivo and in vitro 
models of Traumatic Brain Injury 
Zhang et al. (2017) 
Antidiabetic Adrb3, GLUT4, MCP-1 (L. Wang, Park, et al., 
2018a) 
Supercharged mice, Adrb3, 
GLUT4, MCP-1 
Maeda et al. (2009) 
HRAR, RLAR, PTP1B, AGE Jung et al. (2012) 
Diabetic mice Maeda et al. (2007) 
Skin protective In vivo and in vitro studies (Mio Matsui et al., 
2016) 
Inhibitory effect on tyrosinase 
activity in guinea pigs 
Shimoda et al. (2010) 
Human fibroblast cells (S. J. Heo & Jeon, 
2009a) 
Ikeda et al. (2003).  
Table 3 (continued )    




hypertensive rats (SHRSP)  
Drosophila melanogaster and 
Caenorhabditis elegans 
Lashmanova et al. 
(2015) 
Transcriptome analysis Moskalev et al. (2018) 
Normal human cells LECh4 (81) Guvatova et al. (2020) 
Rat glioma cells model Afzal et al. (2019) 
Hepatoprotection Mice fed a high-fat diet Woo et al. (2010) 
Park et al. (2011) 
Antiplasmodial Plasmodium falciparum Afolayan et al. (2008)  
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promoted differentiation to functional cells (Afzal et al., 2019). Similar 
experiments were developed using the same cell types and same damage 
reagents showing results according to those observed in animal models. 
On human fibroblasts, the treatment with fucoxanthin before the 
exposure to UVB caused an increment dose-dependent in cell survival, 
comparing to untreated cells, the maximum cell survival rate reached 
81.47% with a concentration of 100 μM of the carotenoid (Heo & Jeon, 
2009). As previously mentioned, the fucoxanthin pre-treatment (5 μM) 
of human L02 hepatic cells increased their viability after the exposition 
to H2O2. The authors suggested that the increment of Nrf2 expression 
levels leads to the activation of both cytoprotective enzymes, NQO1 and 
HO-1, which help to palliate oxidative damage (Wang, Park, et al., 
2018a). Arachidonic acid and iron were used to stimulate oxidative 
damage and apoptosis in hepatic cells (Hep G2) pre-treated with fuco-
xanthin extracted from Laminaria japonica. The results showed that the 
fucoxanthin pre-treatment (30 μM/mL) allowed reducing cell death, 
mitochondria dysfunction and oxidative damage and triggered auto-
phagy through the activation of AMP-activated protein kinase (AMPK) 
which promotes the removal of damaged cellular components repre-
senting a fundamental pathway for cell homeostasis (Jang et al., 2018). 
Concordant effects to those described above were observed in human 
umbilical vein endothelial cells exposed to oxidized LDL cell damage, 
confirming that protective effects of fucoxanthin are related to the 
AMPK pathway (Ou et al., 2019). 
Several studies have reported the cytoprotective effects of fucoxan-
thin in vivo animal models. Topical application of a solution with fuco-
xanthin in hairless mice submitted to UVB-induced skin damage 
demonstrated to prevent wrinkle formation, epidermal hypertrophy and 
other sings of photo-aging and oxidative damage (Urikura et al., 2011). 
Mice were exposed to excessive UV radiation and the results showed that 
topic treatment with fucoxanthin prevented UV-induced sunburns and 
also cured four days sunburns (Matsui et al., 2016). Similarly, on an in 
vivo rabbit model submitted to intense light to induce retinal damage, it 
was found that fucoxanthin protected photoreceptor cells (rod cells and 
cone cells) (Liu et al., 2016). In the previously cited study, conducted on 
rats using DEN to stimulate hepatocarcinogenesis, it was demonstrated 
that fucoxanthin reverted significantly the cytotoxic effects of DEN 
when compared against rats without fucoxanthin administration (Jin 
et al., 2019). Finally, as observed in in vitro models, the oral adminis-
tration of fucoxanthin (10 mg/kg) increased the levels of Nrf2 expres-
sion, activating the antioxidant defenses, and reduced the corneal 
damage caused by UVB radiation in vivo rats (Chen et al., 2019). 
3.3. Anticancer activity 
Fucoxanthin is considered an anticancer carotenoid and its activity 
has been demonstrated against a wide range of cancer cell lines, both 
human and animal. Several studies have reported that fucoxanthin ex-
erts different anticancer mechanisms of action, such as inhibition of cell 
proliferation, cell cycle arrest, an increase of intracellular ROS, induc-
tion of apoptosis and anti-angiogenic effects (Bae et al., 2020; Chuyen & 
Eun, 2017; Cianciosi et al., 2018; Kumar et al., 2013; Ou et al., 2019; 
Satomi, 2017). 
Fucoxanthin has been found to inhibit growth and induce apoptosis 
on mouse cell models such as melanoma (B16-F10), embryonic liver 
(BNL CL.2) and neuroblastoma murine cell lines (Neuro2a) (Kim et al., 
2013; Kumar et al., 2013; Satomi, 2017). However, most of the in vitro 
assays have been performed using human cell lines. Fucoxanthin has 
been evaluated over a large number of cell lines such as human leukemia 
cells HL-60, human colorectal adenocarcinoma cell lines Caco-2, DLD-1 
and HT-29, human colorectal carcinoma HCT116, human prostate 
cancer cell lines PC-3, DU145 and LNCaP, breast cancer MCF-7 and 
MDA-MB-231, human male umbilical cord fibroblasts HUC-Fm, urinary 
bladder cancer EJ-1, human neuroblastoma GOTO, human liver cancer 
Hep G2, hepatoma SK-Hep-1 and lung cancer H1299 cell line. Several 
studies have demonstrated the ability of fucoxanthin to induce cell-cycle 
arrest in numerous cancer lines, such as GOTO, human colon carcinoma 
WiDr, HepG2, Burkitt’s and Hodgkin’s lymphoma and T-cell leukemia 
cells. The results showed that fucoxanthin affected the expression of 
cellular molecules and cellular signal transduction pathways, which lead 
to cell cycle arrest (Chuyen & Eun, 2017; Kumar et al., 2013; Satomi, 
2017). Recent studies have reported that fucoxanthin promoted 
apoptosis and reduced cell proliferation in bladder cancer T24 and EJ-1 
cell lines, human glioma cancer U87 and U251 cell lines, human gastric 
adenocarcinoma MGC-803, human liver cancer Hep G2, and breast 
cancer MCF-7 and MDA-MB cell lines (Jin et al., 2018; Neumann et al., 
2019; Yu et al., 2017). Fucoxanthin has been demonstrated to be more 
effective in promoting apoptosis than β-carotene and astaxanthin on the 
colorectal adenocarcinoma cell lines Caco-2, HT-29, and DLD-1 (Hoso-
kawa et al., 2004). Fucoxanthin induced apoptosis on human gastric 
adenocarcinoma SGC-7901 or BGC-823 cells by JAK/STAT pathway, 
which is related to apoptosis, among other processes. Besides, SGC-7901 
presented cell cycle arrest at phase S and BGC-823 at the G2/M phase 
(Yu et al., 2017). In human non-small cells, bronchopulmonary carci-
noma NSCLC-N6 were observed apoptotic cells characteristic, whereas 
in human lung epithelial cells no cytotoxic effects were observed, indi-
cating that fucoxanthin action is a target to carcinogenic cells. Fuco-
xanthin reduced cell proliferation of two human leukemia cell lines, 
erythromyeloblastoid leukemia cell line K562, and the human lym-
phoblastoid cell line TK6, and presents cytotoxic effects against K562 
cells. These results showed that cytotoxic effects were not related to 
apoptosis, but deeper research is necessary to fully understand the 
molecular pathways involved in fucoxanthin cytotoxicity against this 
human leukemia cell lines (Almeida et al., 2018). In this sense, leukemia 
cells (HL-60) were treated with fucoxanthin that induced apoptosis 
through the production of ROS, reduced the levels of the anti-apoptotic 
Bcl-xL protein, triggered the cleavage of caspases and the consecutive 
inactivation of the poly-ADP-ribose polymerase. Similar results were 
observed in prostate cancer (PC-3) cells and cervical adenocarcinoma 
cells (HeLa), in which the fucoxanthin induced caspase-dependent 
apoptosis, modulated by changes in BAX/Bcl-2 proteins related to the 
apoptotic process (Chuyen & Eun, 2017; Kumar et al., 2013; Satomi, 
2017). In human cervical cancer SiHa cells, tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) administration with 
fucoxanthin promoted apoptosis through the suppression of PI3K/Akt 
and NF-κB pathways. These two pathways are strongly related to cell 
proliferation and therefore, to cancer (Jin et al., 2018). In the human 
glioma U251 cell line, the results showed that fucoxanthin extracted 
from microalgae Nitzschia sp induced apoptosis through the production 
of ROS and dysfunction of MAPKs and PI3K/AKT pathways (Wu et al., 
2019). 
But not only the fucoxanthin presents anticancer effects, its two 
metabolites fucoxanthinol, and halocynthiaxanthin have been reported 
to have anti-cancer activity, in many cases showing stronger capacity 
than fucoxanthin. In fact, when fucoxanthin and fucoxanthinol effects 
were tested on PC-3 cells, the IC50 for fucoxanthinol was 2.0 μM while 
for fucoxanthin it was 3.0 μM (Kotake-Nara et al., 2015). Another study 
reported halocynthiaxanthin at 5 μg/mL, completely inhibited GOTO 
human neuroblastoma cell growth, while fucoxanthin, at the same 
concentration, caused an 88% reduction on cell growth. While on leu-
kemia (HL-60), breast cancer (MCF-7) and colorectal adenocarcinoma 
(Caco-2) cells, both metabolite induced apoptosis in a stronger manner 
than fucoxanthin (Chuyen & Eun, 2017; Kumar et al., 2013). In another 
experiment, fucoxanthin and fucoxanthinol were displayed to induce 
apoptosis in both breast cancer MCF-7 and MDA-MB-231 cell lines. 
Nevertheless, only fucoxanthinol reduced the expression of some NF-κB 
pathway members in the MDA-MB-231 cell line (Chuyen & Eun, 2017; 
Kumar et al., 2013; Satomi, 2017). A recent study conducted on human 
adenocarcinoma colorectal cells demonstrated that fucoxanthinol 
induced anoikis, a type of apoptosis that occurs in anchorage-dependent 
cells when they detach from the extracellular matrix or neighbor cells 
(Terasaki, Iida, et al., 2019a). 
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Regarding in vivo studies, fucoxanthin administered in different ways 
has been demonstrated to inhibit many types of cancers. In mice, oral 
administration of fucoxanthin reduced duodenal and liver carcinogen-
esis growth and also the number of aberrant crypt foci in 1,2-dimethyl-
hydrazine-submitted colon and azoxymethane-treated mice (Afrin et al., 
2020; Kim et al., 2013; Kumar et al., 2013; Satomi, 2017). Similarly, 
mice submitted to two carcinogens using azoxymethane and dextran 
sodium sulphate were treated with fucoxanthin showing a reduced 
polyp formation and induced anoikis. The same author used BALB/c 
nu/nu mice to inject them colorectal cancer cells and treated them with 
fucoxanthin administrated via oral. Results showed that fucoxanthin 
reduced the proliferation of the subcutaneous tumors, without produc-
ing cytotoxic effects (Terasaki, Matsumoto, et al., 2019b). Some other 
studies reported that the administration of fucoxanthin suppressed 
tumor growth of primary effusion lymphoma, sarcomas, and osteosar-
coma in mice (Chuyen & Eun, 2017; Kumar et al., 2013; Satomi, 2017). 
Intraperitoneal injection of fucoxanthin has been reported to inhibit 
tumor growth of melanoma (B16F10) and cervical adenocarcinoma 
(HeLa) cell lines implanted in in vivo mice models (Kim et al., 2013; 
Kumar et al., 2013; Satomi, 2017). Ultimately, the topic application of 
fucoxanthin, in combination with 12-O-tetradecanoylphorbol 13-ace-
tate, inhibited skin tumor in mice (Chuyen & Eun, 2017; Kumar et al., 
2013; Satomi, 2017). 
Consequently, both in vitro and in vivo assays using fucoxanthin and 
its metabolites demonstrate that these compounds possess important 
anti-proliferative effects which may be focused on cancer cells. For 
instance, all these results point to fucoxanthin as a promising compound 
to control and treat cancer. 
3.4. Anti-inflammatory activity 
The anti-inflammatory potential of fucoxanthin isolated from a 
brown algae, Myagropsis myagroides, was analyzed through the inhibi-
tion of the production of nitric oxide (NO), one of the determinants of 
inflammation (Heo et al., 2010). This alga was treated using different 
solvents from which the extract obtained using chloroform was the one 
that showed a greater inhibitory effect of NO, being fucoxanthin the 
active substance detected. Fucoxanthin was capable of inhibiting 
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) 
protein expressions, in addition to reducing the expressions of other 
pro-inflammatory factors such as mRNA, tumor necrosis factor-α 
(TNF-α) and interleukins-1b and 6. 
Similarly, another research group discovered that both fucoxanthin 
and its primary metabolite, fucoxanthinol, were able to inhibit NO 
production, reducing inflammation caused by obesity. They also 
concluded that there was a significant inhibition of mRNA expressions of 
interleukin-6, plasminogen activator inhibitor-1 (PAI-1), COX-2 and 
iNOS in Raw 264.7 macrophages co-cultures, as well as in 3 T3-L1 
adipocyte cells by both compounds (Wang, Park, et al., 2018a). There-
fore, the possibilities of achieving very favorable and beneficial results 
with these compounds opens the door to possible and future therapeutic 
applications, since it could contribute to the fight against many in-
flammatory diseases or that involve inflammation. 
A recent study also reports the potential protective effect of fuco-
xanthin on several inflammation-related diseases, due to fucoxanthin’s 
strong antioxidant capacity and gut microbiota regulation. Some of the 
important molecules to this regulation include Nrf2, cAMP response 
element binding protein, extracellular signal-regulated kinase, adeno-
sine monophosphate (AMP)-dependent protein kinase, Akt serine/ 
threonine kinase/phosphatidylinositol-3-kinase, and peroxisome pro-
liferator-activatedreceptorγcoactivator-1α (M. Liu et al., 2020). 
3.5. Antiobesity activity 
Obesity is becoming a worldwide health problem with an increasing 
number of affected people. This pathology appears when food ingested, 
and its proportional kilocalories (kcal), far exceeds the energy used to 
perform daily tasks and activities, so there is an excess of caloric intake 
that it takes accumulated in the body. Several conditions have been 
analyzed as possible triggers of this disease, such as metabolic or dietary 
factors. It has been also studied the capacity of some active compounds 
present in food since some of them can cause changes in metabolism by 
contributing to the imbalance of energy in tissues. Therefore, research 
on possible remedies against this condition is of great interest. One of the 
most promising strategies is the development of diet-induced adaptive 
thermogenesis through the positive regulation of mitochondrial 
uncoupling protein 1 (UCP1). In this sense, fucoxanthin is a key com-
pound, since it is a food component that can favor such thermogenic 
adaptation by regulating UCP1 in both beige, white (WAT) and brown 
adipose tissues (BAT), and managing to increase daily energy expendi-
ture (Miyashita et al., 2020; Miyashita & Hosokawa, 2017). In a study 
carried out in mice and rats, in which the weight of the WAT was 
analyzed, it was shown that the mice fed with fucoxanthin displayed a 
significantly lower weight than the control groups, fed with a diet not 
based on the contribution of this molecule (Maeda et al., 2008). Among 
reducing WAT, fucoxanthin has a systemic effect, reducing total body 
weight. Rodents fed with fucoxanthin displayed UCP1 expression in 
abdominal WAT that involved the oxidation of fatty acids and the 
consequent thermogenesis in WAT mitochondria. On the other hand, the 
consumption of fucoxanthin was able to lower blood glucose levels and 
plasma insulin. Moreover, and as a novel fact, adding fucoxanthin to the 
diet significantly increases hepatic docosahexaenoic acid (DHA) levels 
in rodents, the most important polyunsaturated fatty acid due to its 
functionality (Okada et al., 2008). Another work claimed that fuco-
xanthin obtained from Undaria pinnatifida, and its derivative fucox-
anthinol, produced an inhibitory effect on the differentiation of 
preadipocytes into adipocytes. This effect may be mediated by the 
down-regulation of adipogenic transcription factors, such as peroxisome 
proliferator-activated receptor-c, and that achieves a decrease in adipose 
tissue content in the body (Maeda et al., 2006; Okada et al., 2008). 
Likewise, it has been suggested that such suppression of adipocyte dif-
ferentiation can be generated due to the unique allenic bond present in 
the structure of fucoxanthin and its derivative. Other carotenoids with 
different types of substituents in their structures have been tested, and 
fail to produce the same effect (Kim & Pangestuti, 2011; Okada et al., 
2008). 
Therefore, all these capabilities and attributes associated with the 
intake of fucoxanthin support the importance of this bioactive carot-
enoid in the prevention of metabolic disorders, such as obesity. Never-
theless, deeper evaluations about the mechanism of action of this group 
are necessary for its further therapeutic application (Miyashita et al., 
2020; Miyashita & Hosokawa, 2017). 
3.6. Neuroprotective effect 
In 20 years, neurodegenerative diseases are expected to be placed as 
the second leading cause of death in the world, even overcoming those 
caused by cancer (Ansari et al., 2010; Bjarkam et al., 2001). This is one 
of the reasons why scientists and researchers have given great impor-
tance to developing neuroprotective strategies and therapies in order to 
minimize the impact of these predictions. Neuroprotection can be 
defined as the mechanisms and procedures used to protect neuronal cells 
belonging to the central nervous system (CNS) against possible damage, 
apoptosis, loss of function or accelerated degeneration (Tucci & Bagetta, 
2008). The substances capable of exerting beneficial effects are named 
neuroprotective agents and may have natural or synthetic origin. 
However, and as it happens in other fields, the administration of syn-
thetic compounds is usually associated with side effects. In the case of 
the neuroprotector agents, the described side effects are drowsiness, 
fatigue, dry mouth, imbalance, anxiety or nervousness, among others 
(Narang et al., 2008; Pangestuti & Kim, 2010). In the last years, in order 
to prevent the apparition of these side effects, researchers have opted for 
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searching and studying the neuroprotective abilities of natural com-
pounds. Algae are an emerging source of natural compounds with 
bioactive capabilities, thus their biomolecules are been evaluated in 
order to try to disclose compounds capable of generating neuro-
protection (Pangestuti & Kim, 2011). 
Fucoxanthin extracted and isolated from Hizikia fusiformis, a brown 
alga widely consumed in Korea, Japan, and China, has been demon-
strated to inhibit the expression of N-myc, a proto-oncogene protein, as 
well as the proliferation of GOTO cells, a cell line responsible for human 
neuroblastoma. An amount of fucoxanthin equivalent to 1–10 g/mL is 
enough to inhibit the growth rate of such a cell line (GOTO) at 38%, 
decreasing the rate of progression of this neurodegenerative disease, so 
even though results using fucoxanthin are positive; it will take time to 
combat it (Okuzumi et al., 1990). Another study showed that fucoxan-
thin obtained from wakame also achieved a decrease in cellular damage 
of cortical neurons when hypoxia and oxygen reperfusion conditions 
were induced. Since an excessive amount of ROS usually occurs during 
these processes, the mechanism of action of fucoxanthin, as previously 
exposed, is associated with a radical scavenging activity, producing an 
antioxidant effect. This is especially interesting for the protection of 
neurites since they are very important components of neurons, necessary 
for neuronal development during the embryonic state and also in the 
adult human brain (Khodosevich & Monyer, 2010). 
As explained before fucoxanthin has been also demonstrated to be 
implied on the activation of the Nrf2 pathway and its related genes, such 
as those for the cytoprotective enzymes NQO1 and HO-1, showing that it 
may protect the brain against ischemia/reperfusion (I/R) injury. In this 
study, oxidative stress was significantly alleviated upon fucoxanthin 
treatment, indicating that fucoxanthin might induce Nrf2/HO-1 acti-
vation and thereby leading to attenuation of oxidative stress from ce-
rebral I/R injury. This study indicated that treatment with fucoxanthin 
effectively reduced middle cerebral artery occlusion-induced cerebral I/ 
R injury and the apoptosis of oxygen-glucose deprivation and reoxyge-
nation -treated neurons, and these effects were partly mediated by the 
activation of Nrf2/HO-1 signaling. Therefore, this assay concluded that 
fucoxanthin could be used as a potential supplementary ingredient 
against cerebral I/R injury in the future (Hu et al., 2018). 
The neuroprotective effects of fucoxanthin through the Nrf2- 
pathway were further evaluated by different approaches. As in the 
case of the study were the possible role of Nrf2-antioxidant response 
elements (ARE) and Nrf2-autophagy pathways in the neuroprotective 
effects of fucoxanthin were examined in in vivo and in vitro models of 
Traumatic Brain Injury (TBI). This batch of experiments found that: 
fucoxanthin provided neuroprotection after TBI; specifically, it 
improved neurobehavioral performance, alleviated brain edema and 
decreased lesion volume. Besides the treatment using fucoxanthin 
decreased TBI-induced apoptosis and oxidative stress; attenuated 
apoptosis and oxidative stress through activation of the Nrf2-ARE and 
Nrf2-autophagy pathways (Zhang et al., 2017). 
The global analysis of the results presented above allows confirming 
the neuroprotective capacity that some natural ingredients possess. The 
use of natural compounds is usually considered to produce less or non- 
unwanted side effects, which makes them very interesting compounds 
for including them in the formulation of new foods or drugs (Munekata 
et al., 2019, pp. 53–96). Natural products may represent novel and 
functional ingredients for the treatment and/or prophylaxis of neuro-
degenerative diseases. However, it is necessary to continue with the 
studies, to reach the successive clinical phases, more in vivo studies and, 
subsequently, in humans (Pangestuti & Kim, 2011). 
3.7. Antidiabetic effect 
Fucoxanthin has been confirmed as a substance capable of exerting 
an antidiabetic effect, for example, by regulating the level of blood 
glucose, as well as that of insulin, possibly exerting a promotional effect 
of the β3-adrenergic receptor (Adrb3) and glucose transporter 4 
(GLUT4), as well as an inhibition of the expression of monocyte che-
moattractant protein-1 (MCP-1) (Wang, Park, et al., 2018b). In fact, a 
fucoxanthin-rich lipids fraction obtained from wakame was described to 
possess anti-diabetic properties and demonstrated in mice with obesity 
induced by the hyperlipidemic diet (Bae et al., 2020). According to the 
results, plasma glucose and insulin levels increased significantly in mice 
fed with a high-fat diet, while they decreased in mice given fucoxanthin 
as a dietary supplement. The mechanism of action was associated with 
an increase in Adrb3 and GLUT4 receptors, and a decrease in MCP-1 
expression (Maeda et al., 2009). Interestingly, the hypoglycemic effect 
of fucoxanthin is only observed in mice models with a dietary pathology 
induced, such as diabetes (Maeda et al., 2007), since overfed but healthy 
mice, it means not suffering from diabetes or obesity, the effect of 
fucoxanthin on reducing the glycemia was not observed (Maeda et al., 
2009; Park et al., 2011; Woo et al., 2009). However, a decrease in 
postprandial glucose concentration, plasma insulin level and insulin 
resistance was observed in the overfed and obese mice (Maeda et al., 
2006; Park et al., 2011). It was determined that the antidiabetic effect of 
this marine carotenoid may be mainly due to two possible biological 
mechanisms: the effect of fucoxanthin and its accumulated metabolites 
in visceral WAT, which regulate the release of cell mediators, and/or the 
regulation of the expression of GLUT4 and its appearance in the cell 
membrane (Miyashita et al., 2011, 2013) 
Another work that analyzed the antidiabetic capacity of fucoxanthin, 
also extracted from wakame, showed different mechanisms of action. 
Results displayed that this compound was able to inhibit the activities of 
certain human enzymes, related to the metabolic diabetes disease, such 
as recombinant aldose reductase (HRAR), rat lens aldose reductase 
(RLAR), protein tyrosine phosphatase 1B (PTP1B), and advanced gly-
cation end-product (AGE) formation (Jung et al., 2012). 
3.8. Skin protective effect 
Nowadays, the harmful effect of UV radiation is well-known and 
wide world recognized. Mild or moderate exposure to this radiation is 
enough to create damage to the skin, leading to photosensitivity, and 
even burns. Among the already cited properties, fucoxanthin has been 
also demonstrated to have a positive effect in preventing these damages 
caused by UV. In vitro and in vivo studies carried out with fucoxanthin 
obtained from wakame supported its skin protector feature. When 
fucoxanthin was tested in in vitro assay it was observed that it decreased 
the production of intracellular ROS, triggered after exposure of dermal 
fibroblasts to UV radiation, as much as other compounds with strong 
antioxidant capacity, such as N- acetylcysteine (NAC). In vivo results, 
showed a stronger efficiency of fucoxanthin since it had skin protective 
effect against burns and filaggrin disorder (filament aggregating pro-
tein) induced by radiation, while NAC or clobetasol (a drug from the 
group of corticosteroids) were unable to protect the dermal layers. The 
data obtained suggest that the dermo-protective capacity of fucoxanthin 
against burns induced by UV radiation can be explained through the 
promotion of filaggrin, which generates a protective dermal barrier, 
instead of its ROS-sensing effect (Matsui et al., 2016). 
Fucoxanthin extracted from different sources, such as Laminaria 
japan, was also reported to exert an inhibitory effect on tyrosinase ac-
tivity in in vivo assays performed on guinea pigs. Animals previously 
exposed to UV radiation and treated with fucoxanthin displayed a 
reduction of the harmful effects of irradiation. It was demonstrated that 
an oral administration of fucoxanthin produced a suppression of tran-
scription of the melanogenesis factor, due to the inhibition of dermal 
mRNA expression related to this disease (Shimoda et al., 2010). The 
photoprotective capacity of the fucoxanthin has been also related to the 
remediation of DNA damage and its potent antioxidant activity, in 
human fibroblast cells (Heo & Jeon, 2009). Therefore, it can be 
concluded that oral administration of fucoxanthin, either as a food 
supplement or as a drug, can reduce or even prevent the negative effects 
induced by exposure to UV radiation, such as the appearance of 
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melanomas. 
3.9. Geroprotective activity 
The rate of aging and longevity is directly correlated with the or-
ganism’s ability to effectively respond to exterior or physiological stress. 
Thus, an approach to increase lifespan is through the pharmacological 
activation of stress-defense mechanisms. Fucoxanthin has been evalu-
ated as a potential geroprotective agent. A recent study analyzed the 
effects of fucoxanthin in the lifespan of Drosophila melanogaster and 
Caenorhabditis elegans. The use of fucoxanthin decreased flies fecundity, 
increased the spontaneous locomotor activity and improve the resis-
tance to oxidative stress which translated into an enhanced median and 
maximum lifespan of both species (Lashmanova et al., 2015). With the 
aim of developing potential drugs to prolong human life and prevent the 
development of age-related diseases, further studies were made to 
determine signaling pathways affected by this carotenoid both at mo-
lecular and systemic level. At the organism level, fucoxanthin improved 
nighttime sleep, fertility and intestinal barrier function. To determine 
the differentially expressed genes involved a transcriptome analysis was 
performed. Up to 17 KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathways were involved. Those were related to longevity, such as 
mTOR, MAPK, Wnt, Hippo and Notch, translation, oxidative phos-
phorylation, autophagy, apoptosis, glycolysis, neurogenesis, immune 
response, sleep, and response to DNA damage. Thus, fucoxanthin was 
demonstrated to alter the expression of longevity associated genes which 
may confer it geroprotective effects (Moskalev et al., 2018). 
Another study, evaluated fucoxanthin’s antioxidant activity in em-
bryonic lung fibroblasts under oxidative stress conditions using a new 
generation sequence tool, RNA-seq. Transcriptomic changes were stud-
ied during the replicative senescence of fibroblasts in the presence of 
fucoxanthin. Results showed an increment in the expression level of 
genes related to the Nrf2/ARE pathway. Besides, when analyzing the 
enriched KEGG pathways, it was evident that fucoxanthin was able to 
alter cellular processes like lipid metabolism, ribosome biogenesis and 
cell cycle regulation and the previously mentioned Wnt, JAK-STAT, and 
FoxO signaling pathways. Thus, fucoxanthin may represent an alterna-
tive molecule to treat or, at least prevent, age-related diseases (Guvatova 
et al., 2020). 
Lastly, the anti-stress and differentiation-inducing potential of 
fucoxanthin were tested through a model with rat glioma cells. At low 
and nontoxic concentrations, fucoxanthin was able to protect cells 
against heat-induced protein misfolding, aggregation of proteins, UV- 
induced DNA damage and heavy metals. Long term treatments of gli-
oma cells using fucoxanthin induced physiological differentiation into 
astrocytes, which suggests the great potential of this carotenoid for 
preventing and protecting against age-related pathologies (Afzal et al., 
2019). 
3.10. Other biological activities 
Some studies show that terpenes (a chemical group to which xan-
thophylls belong), specifically diterpenes, from Dictyota dichotoma 
seaweed, among others, can reduce the risk of hypertension and heart 
failure. Diterpenes constitute a pharmacological group of compounds 
that are widely used in the treatment of cardiovascular diseases. Fuco-
xanthin is a molecule that binds to nitrogen through strong bonds, so it is 
also able to reduce nitric oxide levels, thereby decreasing its vasodilator 
efficacy (Agatonovic-Kustrin et al., 2018). This data has been supported 
by an additional work where fucoxanthin extracted from wakame was 
able to reduce the development of hypertension, as well as its associated 
problems, in stroke-prone spontaneously hypertensive rats (Ikeda et al., 
2003; Miyashita et al., 2020). 
Similarly, the effects of fucoxanthin on other disorders have been 
studied, demonstrating that it is capable of inhibiting differentiation of 
the RAW264.7 macrophage cell line, a cell line that can derive in 
osteoclast cells if stimulated with the activating ligand of the NF-kB 
receptor, reducing osteoclastogenesis (Das et al., 2010). 
Concerning lipid metabolism, fucoxanthin has been also demon-
strated in in vivo assays to reduce the triglyceride concentration in 
plasma which increases the content of lipids in faces. Additionally, the 
hepatic lipid content was reduced in the group fed with fucoxanthin 
which was associated with a parallel reduction in the enzymatic activity 
of the hepatic tissue. (Woo et al., 2010). Other authors corroborate these 
results by the associating the same reasons (a possible reduction in he-
patic synthesis of fatty acids, due to the decrease in the activity of related 
enzymes). This study also demonstrated that the effect of the fucoxan-
thin is not dose-dependent since the same results were observed when 
using doses of 0.05% and 0.2%, thus the lower administration dose was 
enough to produce these benefits. Besides, and as a complementary 
activity, fucoxanthin has been described to possess the ability to 
significantly activate glycolytic enzymes, such as hepatic glucokinase, 
regulating hepatic levels of glucokinase/glucose-6-phosphatase and 
glycogen in mice fed with excess fat (Park et al., 2011). 
Moreover, fucoxanthin also has been demonstrated to have anthel-
mintic properties. Malaria is a tropical and subtropical disease caused by 
the protozoan Plasmodium falciparum, a parasite that is transmitted by 
mosquito. An extract obtained from the brown seaweed Sargassum het-
erophyllum, rich in fucoxanthin, sargahydroquinoic acid, sargaquinoic 
acid and sargaquinal, was tested against Plasmodium falciparum. The 
extract produced an effective response against the parasite, so then the 
individual components were purified and newly tested. The fraction 
containing fucoxanthin was the one that showed the greatest anthel-
mintic potential. Authors associated such antimalarial activity with the 
strong antioxidant capacity of the algal molecules, although they also 
encouraged new tests to deepen the mechanism of action (Afolayan 
et al., 2008). 
Another study tested the effects of fucoxanthin in men infertility, 
since the oxidative stress has been recognized as one of the triggering 
causes of this pathology that can affect 5 of 10 men. A rich fucoxanthin 
extract obtained from Sargassum glaucescens was evaluated in a 
lipopolysaccharide-induced inflammation model in macrophages and in 
a Cisplatin-induced model that replicates reproductive damages in 
hamsters. The administration of fucoxanthin for 5 days reduced the level 
of malondialdehyde and reactive oxygen species in macrophages and 
rats’ testis. Besides it showed protective effects on mitochondrial 
membrane potential, related to its antioxidant and anti-inflammatory 
capacity. Furthermore, the alpha-glucosidase activity and testosterone 
levels were improved and the sperm count also increased while the 
sperm abnormality decreased. These findings suggest that fucoxanthin 
extracts can be used as an alternative treatment for testicular damage 
(Wang et al., 2020). 
4. Bioavailability,Toxicity, and stability 
Fucoxanthin absorption is affected by the amount and type of lipids 
and fiber consumed in the daily diet, as well as by the food matrix in 
which this carotenoid is included (Bohn, 2008). When fucoxanthin 
(Fig. 1A) is ingested it undergoes hydrolyzing in the gastrointestinal 
tract resulting in fucoxanthinol (Fig. 1 B) which is further transformed 
into amarouciaxanthin A (Fig. 1C), mostly in the hepatic tissue (Asai 
et al., 2004). The esterification step, in addition to allowing the trans-
port and distribution of fucoxanthin, transforms it into a non-polar 
molecule of greater bioavailability, thus reducing its possible toxic ef-
fects, protecting the organism (Sugawara et al., 2002, 2009). 
As explained in section 1.2, differences among species have been 
observed by few authors who have underlined that for obtaining similar 
results mice required the administration of higher doses of fucoxanthin 
than humans (Abidov et al., 2010; Hashimoto et al., 2012; Maeda et al., 
2009). The explanation of the differences between the effective dose in 
humans and mice may be due to different reasons. The lower concen-
tration of fucoxanthin or fucoxanthinol detected or needed for having 
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effects on mice may be due to the faster and different pharmacokinetic 
profile that small and short-lived animals possess which may trigger 
quicker detoxification pathways (Mordenti, 1986). It has been also 
stated that different absorption rates may be involved in the sensitivity 
to the fucoxanthin or its metabolites since the vegetable or food matrix 
in which the pigment is wrapped directly influences the absorption rate 
of this compound. A study on the solubility of fucoxanthin in different 
micelles demonstrated the variability of the process. The results dis-
played that the greatest solubility was achieved with the long-chain 
triacylglycerols (TAG) micelles, followed by medium-chain TAG and, 
finally, those of indigestible oil (orange/mineral oil) (Salvia-Trujillo 
et al., 2015). Fucoxanthin naturally found in alga tissues is mainly 
embedded in a matrix of glycoglycerolipids. A greater presence of these 
compounds is associated with greater absorption of fucoxanthin, since 
the ingestion of glycoglycerolipids favors the formation of lyso-type 
compounds that increase and facilitate the absorption and, therefore, 
its bioavailability (Kotake-Nara et al., 2015; Miyashita et al., 2013). 
As previously mentioned, algae have been part of the Asian diet for 
generations, algae that include as beneficial molecules as fucoxanthin in 
their composition, so, over time, safety and toxicity tests have been 
carried out in animals. For example, in a study conducted by (Beppu 
et al., 2009) it was found that the administration to mice of a single dose, 
whether it was 1000 or 2000 mg/kg of fucoxanthin, did not produce 
abnormalities, much less mortality. Therefore, they conducted a new 
trial in which mice were also given a repeated treatment of 500 or 1000 
mg/kg for 30 days, concluding that there were no adverse effects after 
this treatment. Similarly (Kadekaru et al., 2008), also reported no 
toxicity in their study carried out by applying purified fucoxanthin in 
rats. Moreover, metabolic derivatives of fucoxanthin such as fucox-
anthinol (Fig. 1), also showed no significant adverse effects or muta-
genicity in in vivo trials, and it was found that fucoxanthinol reaches 
human plasma after the consumption of brown algae, specifically, by 
U. pinnatifida (Asai et al., 2004; Miyashita & Hosokawa, 2017). 
Fucoxanthin, like most carotenoids from marine environments, has 
low toxicity. A study conducted with oily extract rich in fucoxanthin 
extracted from the Chaetoceros sp. microalgae used to analyze genotox-
icity in mice through the bacterial mutation and the micronucleus tests 
concluded that no signs of toxicity were observed. In another study 
conducted in mice, the results showed the safety of fucoxanthin, as no 
adverse effects were observed, even though fucoxanthin induced a he-
patic stimulation that resulted in the production of an omega-3 fatty 
acid, DHA, in large quantities (Okada et al., 2008). In addition, a study 
in rats showed that the mean lethal dose (LD50) in a single administra-
tion of fucoxanthin amounted to more than 2 g/kg of body weight, while 
no mortality or abnormalities were observed in a 13-week treatment 
using 200 mg of fucoxanthin/kg/day (Muradian et al., 2015). On the 
other hand, in a study in humans, a daily supplement of 10 mg of 
fucoxanthin was administered. When the treated group was compared 
against the control one, with a placebo supplement administered, no 
adverse side effects were reported. These promising results regarding 
the absorption, bioavailability, distribution, non-toxicity, biocompati-
bility, and bioactivity of fucoxanthin support the conduct of future and 
more in-depth clinical trials in humans (Holt, 2008). However, for the 
further development of clinical trials, the stability of the fucoxanthin has 
to be considered. The degradation of the putative fucoxanthin may 
modify the absorbance degree and the initial properties of the molecule. 
The most used presentations of fucoxanthin (free, emulsified or encap-
sulated) are briefly analyzed for the development of food or cosmetic 
products. When using free fucoxanthin obtained from Sargassum binderi 
at different pH conditions it was observed that at both very acidic (pHs 
of 1 and 3) and in very alkaline environments (pHs of 9, 11 and 13) 
fucoxanthin rich extracts suffered strong degradation, while a pH range 
between 5 and 7 kept their stability (Yip et al., 2014). Another deter-
minant of carotenoid stability are temperature and light (López et al., 
2019; Ye & Eitenmiller, 2005). Regarding the temperature, no signifi-
cant differences were found after storing extracts rich in fucoxanthin at 
4 ◦C or 25 ◦C (p > 0.05) for one month, at 50 ◦C, a significant decrease 
was detected after 3 weeks of storage. In terms of light exposition, ex-
tracts preserved in the dark were more stable than samples exposed to 
light (Yip et al., 2014). Another study conducted on the stability of 
fucoxanthin after its emulsification in an oil/water system showed no 
stability efficiency for fucoxanthin, and all its trans-, 13-cis and 13′-cis 
isomers, except for the 9′-cis isomer. As in the case of the free molecule, 
low values of pH reduce the stability of this isomer while it was even 
capable of considerably increase in concentration under a neutral pH of 
7.5. Similarly, in the emulsion, the increase of temperature greatly 
promoted the degradation of the molecules (Zhao et al., 2019). The third 
alternative for preserving fucoxanthin is through the encapsulation, a 
process that allows the isolation of substances that are not very stable or 
difficult to apply to formulations by enclosing them in a capsule. This 
system may provide an exact dosage in a comfortable administration 
format which converts it in a method that facilitates the adherence to the 
treatment by the consumer (Taofiq et al., 2018). The stability and 
bioavailability of fucoxanthin when encapsulated, using different 
nanogels based on mixing variable amounts of chitosan (C) and glyco-
lipid (G) or sodium tripolyphosphate (ST) has been evaluated. Fuco-
xanthin remained more stable when introduced into C:G nanogels than 
when embedded in C nanogels. The presence of G stabilizes this carot-
enoid and extends it up to nearly two days. In terms of bioavailability, C: 
G nanogels offered the highest rate with 68% (C nanogels 51%, and G 
nanogels, 35%) (Ravi & Baskaran, 2015). 
Therefore, the ideal conditions to incorporate fucoxanthin into for-
mulations, whether pharmaceutical, or as a food ingredient would be 
encapsulated and embedded in solutions with pH 5 to 7 kept stored both 
in a refrigerator at 4 ◦C and room temperature of 25 ◦C, or up to 50 ◦C 
but for periods shorter than 3 weeks in order to keep the features of the 
ingredient. 
5. Future trends 
Algae-extracted fucoxanthin represents a natural molecule with a 
wide range of noteworthy features and bioactivities with many different 
possible applications. For instance, it is important to find a viable way to 
exploit these properties in food, cosmetics, and even in the pharma-
ceutical industries. The growing scientific evidence from in vitro and in 
vivo studies have shown that fucoxanthin has great potential in the 
prevention of illnesses, and also, in the care of human health. As a 
carotenoid, fucoxanthin is a potent antioxidant that protects free radical 
damage cells. A diet rich in fucoxanthin may help to reduce the accu-
mulation of body fat and modulate the levels of glucose and insulin in 
the blood. The administration of fucoxanthin has been shown to be safe, 
without secondary effects and even providing other health benefits, 
including cardiovascular protection, inflammatory activity, anti-cancer 
activity and neuroprotective effect. In addition, it has been shown to 
be an effective chelator of heavy and toxic metals. All of these biological 
and chemical properties prove that fucoxanthin is a very interesting 
component to be included in the formulation of functional foods or 
drugs. Nevertheless, despite the great advances in the characterization 
of its biological activities, the biosynthetic route of fucoxanthin in the 
brown algae is still not fully understood. Therefore, further studies 
deepening this area should be performed to maximize the application of 
fucoxanthin. 
The potential applications of this pigment are very promising; 
however, they are limited because the commercialization of fucoxanthin 
is almost non-existent. Its production must face several challenges since 
its chemical synthesis represents a complex process that is not efficient 
and the extraction method from marine organisms has been not stan-
dardized. The main characteristic of a profitable product is to be ob-
tained by using simple, fast and based on low-cost technologies. This 
work provides an overview of different extraction conditions that may 
help in the standardization of the process, especially important at an 
industrial level. The optimization of the extraction technique permits 
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maximizing the yield and reducing its production costs related to solvent 
and energy consumption and helping to guide the choice for an efficient 
and sustainable way to produce extracts rich in fucoxanthin. Thus, 
future and innovative studies regarding efficient, quick and fast 
extraction methods can speed up the progress towards its 
commercialization. 
Besides, even though carotenoids can be artificially synthesized, 
following laboratory protocols, their extraction from algae presents 
many advantages. In the specific case of fucoxanthin, the accessibility to 
the natural producers, mostly algae, convert this pigment in an eco-
nomic and ecological alternative that provides a natural ingredient 
avoiding safety issues prompted using chemical compounds. However, 
the extraction yield of fucoxanthin has been found to be very variable 
depending on the selected species and the recovery technique as 
demonstrated by the data provided from the analyzed scientific litera-
ture. Therefore, the main aim of this work has been to underline the best 
algae species in terms of fucoxanthin production and the most promising 
extraction and purification methods, while offering a complete pano-
rama of the described bioactivities of fucoxanthin which includes 
bioavailability, administration via, doses and stability of the molecule 
under different conditions. 
Acknowledgments 
The research leading to these results was funded by FEDER under the 
program Interreg V Spain-Portugal (POPTEC, ref. 0377-Iberphenol-6-E); 
by MICINN supporting the Ramón&Cajal grant for M.A. Prieto (RYC- 
2017-22891); by Xunta de Galicia and University of Vigo supporting the 
post-doctoral grant of M.Fraga-Corral (ED481B-2019/096), the pre- 
doctoral grants for A.G. Pereira (ED481A-2019/0228) and P. García- 
Oliveira (ED481A-2019/295); by Axudas Conecta Peme (Xunta de 
Galicia) supporting the IN852A 2018/58 NeuroFood Project and Alga-
Mar (www.algamar.com) for supporting the pre-doctoral grant for C. 
Lourenço-Lopes; NANOEATERS Project (0181_NANOEATERS_01_E) for 
supporting the pre-doctoral work of C. Jimenez-Lopez; EcoChestnut 
Project (Erasmus+KA202) for supporting the work of M. Carpena; Ibero- 
American Program on Science and Technology (CYTED - AQUA-CIBUS, 
P317RT0003) and UP4HEALTH Project (H2020-BBI-JTI-2019) for 
financial support. 
References 
Abidov, M., Ramazanov, Z., Seifulla, R., & Grachev, S. (2010). The effects of XanthigenTM 
in the weight management of obese premenopausal women with non-alcoholic fatty 
liver disease and normal liver fat. Diabetes, Obesity and Metabolism, 12(1), 72–81. 
https://doi.org/10.1111/j.1463-1326.2009.01132.x 
Afolayan, A. F., Bolton, J. J., Lategan, C. A., Smith, P. J., & Beukes, D. R. (2008). 
Fucoxanthin, tetraprenylated toluquinone and toluhydroquinone metabolites from 
Sargassum heterophyllum inhibit the in vitro growth of the malaria parasite 
Plasmodium falciparum. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 
63, 848–852. https://doi.org/10.1515/znc-2008-11-1211 
Afrin, S., Giampieri, F., Gasparrini, M., Forbes-Hernández, T. Y., Cianciosi, D., Reboredo- 
Rodriguez, P., Zhang, J., Manna, P. P., Daglia, M., Atanasov, A. G., & Battino, M. 
(2020). Dietary phytochemicals in colorectal cancer prevention and treatment: A 
focus on the molecular mechanisms involved. Biotechnology Advances, 38, 107322. 
https://doi.org/10.1016/j.biotechadv.2018.11.011 
Afzal, S., Garg, S., Ishida, Y., Terao, K., Kaul, S. C., & Wadhwa, R. (2019). Rat glioma cell- 
based functional characterization of anti-stress and protein deaggregation activities 
in the marine carotenoids, astaxanthin and fucoxanthin. Marine Drugs, 17(3), 189. 
https://doi.org/10.3390/md17030189 
Agatonovic-Kustrin, S., Kustrin, E., Angove, M. J., & Morton, D. W. (2018). A screening 
method for cardiovascular active compounds in marine algae. Journal of 
Chromatography A, 1550, 57–62. https://doi.org/10.1016/j.chroma.2018.03.054 
Airanthi, M. K. W. A., Sasaki, N., Iwasaki, S., Baba, N., Abe, M., Hosokawa, M., & 
Miyashita, K. (2011). Effect of brown seaweed lipids on fatty acid composition and 
lipid hydroperoxide levels of mouse liver. Journal of Agricultural and Food Chemistry, 
59(8), 4156–4163. https://doi.org/10.1021/jf104643b 
Almeida, T. P., Ferreira, J., Vettorazzi, A., Azqueta, A., Rocha, E., & Ramos, A. A. (2018). 
Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs 
imatinib and doxorubicin, in CML cell lines. Environmental Toxicology and 
Pharmacology, 59, 24–33. https://doi.org/10.1016/j.etap.2018.02.006 
Ansari, J. A., Siraj, A., & Inamdar, N. N. (2010). Pharmacotherapeutic approaches of 
Parkinson’s disease. International Journal of Pharmacology, 6(5), 584–590. https:// 
doi.org/10.3923/ijp.2010.584.590 
Asai, A., Sugawara, T., Ono, H., & Nagao, A. (2004). Biotransformation of fucoxanthinol 
into amarouciaxanthin a in mice and HepG2 cells: formation and cytotoxicity of 
fucoxanthin metabolites. Drug Metabolism and Disposition, 32, 205–211. https://doi. 
org/10.1124/dmd.32.2.205 
Asai, A., Yonekura, L., & Nagao, A. (2008). Low bioavailability of dietary 
epoxyxanthophylls in humans. British Journal of Nutrition, 100(2), 273–277. https:// 
doi.org/10.1017/S0007114507895468 
Bae, M., Kim, M. B., Park, Y. K., & Lee, J. Y. (2020). Health benefits of fucoxanthin in the 
prevention of chronic diseases. Biochimica et Biophysica Acta (BBA) - Molecular and 
Cell Biology of Lipids, 1865(11), 158618. https://doi.org/10.1016/j. 
bbalip.2020.158618 
Barros, L., Cabrita, L., Boas, M. V., Carvalho, A. M., & Ferreira, I. C. F. R. (2011). 
Chemical, biochemical and electrochemical assays to evaluate phytochemicals and 
antioxidant activity of wild plants. Food Chemistry, 27(4), 1600–1608. https://doi. 
org/10.1016/j.foodchem.2011.02.024 
Baskaran, V., Sangeetha, K. R., & Bhaskar, N. (2009). Comparative effects of β-carotene 
and fucoxanthin on retinol deficiency induced oxidative stress in rats. Molecular and 
Cellular Biochemistry, 331(1–2), 59–67. https://doi.org/10.1007/s11010-009-0145-y 
Beppu, F., Niwano, Y., Tsukui, T., Hosokawa, M., & Miyashita, K. (2009). Single and 
repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. 
Journal of Toxicological Sciences, 34(5), 501–510. https://doi.org/10.2131/jts.34.501 
Billakanti, J. M., Catchpole, O. J., Fenton, T. A., Mitchell, K. A., & Mackenzie, A. D. 
(2013). Enzyme-assisted extraction of fucoxanthin and lipids containing 
polyunsaturated fatty acids from Undaria pinnatifida using dimethyl ether and 
ethanol. Process Biochemistry, 48(12), 1999–2008. https://doi.org/10.1016/j. 
procbio.2013.09.015 
Bjarkam, C. R., Sørensen, J. C., Sunde, N. A., Geneser, F. A., & Østergaard, K. (2001). 
New strategies for the treatment of Parkinson’s disease hold considerable promise 
for the future management of neurodegenerative disorders. Biogerontology, 2(3), 
193–207. https://doi.org/10.1023/A:1011565207964 
Bjørnland, T., & Aguilar-Martinez, M. (1976). Carotenoids in red algae. Phytochemistry, 
15(2), 291–296. https://doi.org/10.1016/S0031-9422(00)89006-8 
Bohn, T. (2008). Bioavailability of non-provitamin A carotenoids. Current Nutrition & 
Food Science, 4, 240–258. https://doi.org/10.2174/157340108786263685 
Chen, S. J., Lee, C. J., Lin, T. B., Peng, H. Y., Liu, H. J., Chen, Y. S., & Tseng, K. W. (2019). 
Protective effects of fucoxanthin on ultraviolet B-induced corneal denervation and 
inflammatory pain in a rat model. Marine Drugs, 17(3), 152. https://doi.org/ 
10.3390/md17030152 
Chuyen, H. Van, & Eun, J. B. (2017). Marine carotenoids: Bioactivities and potential 
benefits to human health. In Critical reviews in food science and nutrition (Vol. 57, pp. 
2600–2610). Taylor & Francis. https://doi.org/10.1080/10408398.2015.1063477 
Cianciosi, D., Varela-Lopez, A., Forbes-Hernandez, T. Y., Gasparrini, M., Afrin, S., 
Reboredo-Rodriguez, P., Zhang, J. J., Quiles, J. L., Nabavi, S. F., Battino, M., & 
Giampieri, F. (2018). Targeting molecular pathways in cancer stem cells by natural 
bioactive compounds. Pharmacological Research, 135, 150–165. https://doi.org/ 
10.1016/j.phrs.2018.08.006 
Das, S. K., Ren, R., Hashimoto, T., & Kanazawa, K. (2010). Fucoxanthin induces apoptosis 
in osteoclast-like cells differentiated from RAW264.7 cells. Journal of Agricultural and 
Food Chemistry, 58, 6090–6095. https://doi.org/10.1021/jf100303k 
Dawczynski, C., Schubert, R., & Jahreis, G. (2007). Amino acids, fatty acids, and dietary 
fibre in edible seaweed products. Food Chemistry, 103, 891–899. https://doi.org/ 
10.1016/j.foodchem.2006.09.041 
Dillehay, T. D., Ramírez, C., Pino, M., Collins, M. B., Rossen, J., & Pino-Navarro, J. D. 
(2008). Monte verde: Seaweed, food, medicine, and the peopling of south America. 
Science, 320(5877), 784–786. https://doi.org/10.1126/science.1156533 
D’Orazio, N., Gemello, E., Gammone, M. A., De Girolamo, M., Ficoneri, C., & Riccioni, G. 
(2012). Fucoxantin: A treasure from the sea. Marine Drugs, 10, 604–616. https://doi. 
org/10.3390/md10030604 
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López, C. J., Caleja, C., Prieto, M. A. A., Barreiro, M. F., Barros, L., & Ferreira, I. C. F. R. 
(2018). Optimization and comparison of heat and ultrasound assisted extraction 
techniques to obtain anthocyanin compounds from Arbutus unedo L. Fruits. Food 
Chemistry, 264(April), 81–91. https://doi.org/10.1016/j.foodchem.2018.04.103 
López, C. J., Caleja, C., Prieto, M. A., Sokovic, M., Calhelha, R. C., Barros, L., & 
Ferreira, I. C. F. R. (2019). Stability of a cyanidin-3-O-glucoside extract obtained 
from Arbutus unedo L. and incorporation into wafers for colouring purposes. Food 
Chemistry, 275, 426–438. June 2018. 
Maeda, H., Hosokawa, M., Sashima, T., & Miyashita, K. (2007). Dietary combination of 
fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and 
decreases blood glucose in obese/diabetic KK-A y mice. Journal of Agricultural and 
Food Chemistry, 55(19), 7701–7706. https://doi.org/10.1021/jf071569n 
Maeda, H., Hosokawa, M., Sashima, T., Murakami-Funayama, K., & Miyashita, K. (2009). 
Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity 
conditions in a murine model. Molecular Medicine Reports, 2, 897–902. https://doi. 
org/10.3892/mmr-00000189 
Maeda, H., Hosokawa, M., Sashima, T., Takahashi, N., Kawada, T., & Miyashita, K. 
(2006). Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte 
differentiation in 3T3-L1 cells. International Journal of Molecular Medicine, 18, 
147–152. 
Maeda, H., Tsukui, T., Sashima, T., Hosokawa, M., & Miyashita, K. (2008). Seaweed 
carotenoid, fucoxanthin, as a multi-functional nutrient. Asia Pacific Journal of Clinical 
Nutrition, 17(SUPPL. 1), 196–199. 
Maoka, T., Fujiwara, Y., Hashimoto, K., & Akimoto, N. (2007). Characterization of 
fucoxanthin and fucoxanthinol esters in the Chinese surf clam, mactra chinensis. 
Journal of Agricultural and Food Chemistry, 55, 1563–1567. https://doi.org/10.1021/ 
jf063139n 
Matsui, M., Tanaka, K., Higashiguchi, N., Okawa, H., Yamada, Y., Tanaka, K., Taira, S., 
Aoyama, T., Takanishi, M., Natsume, C., Takakura, Y., Fujita, N., Hashimoto, T., & 
Fujita, T. (2016). Protective and therapeutic effects of fucoxanthin against sunburn 
caused by UV irradiation. Journal of Pharmacological Sciences, 132(1), 55–64. 
https://doi.org/10.1016/j.jphs.2016.08.004 
Matsumoto, M., Hosokawa, M., Matsukawa, N., Hagio, M., Shinoki, A., Nishimukai, M., 
Miyashita, K., Yajima, T., & Hara, H. (2010). Suppressive effects of the marine 
carotenoids, fucoxanthin and fucoxanthinol on triglyceride absorption in lymph 
duct-cannulated rats. European Journal of Nutrition, 49(4), 243–249. https://doi.org/ 
10.1007/s00394-009-0078-y 
McClure, D. D., Luiz, A., Gerber, B., Barton, G. W., & Kavanagh, J. M. (2018). An 
investigation into the effect of culture conditions on fucoxanthin production using 
the marine microalgae Phaeodactylum tricornutum. Algal Research, 29, 41–48. https:// 
doi.org/10.1016/j.algal.2017.11.015. November 2017. 
Mikami, K., & Hosokawa, M. (2013). Biosynthetic pathway and health benefits of 
fucoxanthin, an algae-specific xanthophyll in brown seaweeds. International Journal 
of Molecular Sciences, 14, 13763–13781. https://doi.org/10.3390/ijms140713763 
Miyashita, K., Beppu, F., Hosokawa, M., Liu, X., & Wang, S. (2020). Bioactive 
significance of fucoxanthin and its effective extraction. Biocatalysis and Agricultural 
Biotechnology, 26(March), 101639. https://doi.org/10.1016/j.bcab.2020.101639 
Miyashita, K., & Hosokawa, M. (2017). Fucoxanthin in the management of obesity and its 
related disorders. Journal of Functional Foods, 36, 195–202. https://doi.org/ 
10.1016/j.jff.2017.07.009 
C. Lourenço-Lopes et al.                                                                                                                                                                                                                       
Trends in Food Science & Technology 117 (2021) 163–181
180
Miyashita, K., Mikami, N., & Hosokawa, M. (2013). Chemical and nutritional 
characteristics of brown seaweed lipids: A review. Journal of Functional Foods, 5(4), 
1507–1517. https://doi.org/10.1016/j.jff.2013.09.019 
Miyashita, K., Nishikawa, S., Beppu, F., Tsukui, T., Abe, M., & Hosokawa, M. (2011). The 
allenic carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. 
Journal of the Science of Food and Agriculture, 91(7), 1166–1174. https://doi.org/ 
10.1002/jsfa.4353 
Mordenti, J. (1986). Man versus beast: Pharmacokinetic scaling in mammals. Journal of 
Pharmaceutical Sciences, 75(11), 1028–1040. https://doi.org/10.1002/ 
jps.2600751104 
Moskalev, A., Shaposhnikov, M., Zemskaya, N., Belyi, A., Dobrovolskaya, E., Patova, A., 
Guvatova, Z., Lukyanova, E., Snezhkina, A., & Kudryavtseva, A. (2018). 
Transcriptome analysis reveals mechanisms of geroprotective effects of fucoxanthin 
in Drosophila. BMC Genomics, 19(Suppl 3). https://doi.org/10.1186/s12864-018- 
4471-x 
Munekata, P. E. S., Pateiro, M., Barba, F. J., Dominguéz, R., Gagaoua, M., & 
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